



ANNUAL FINANCIAL REPORT

2019-2020

Selected Financial and Other Statistical Highlights

Fiscal Years Ended June 30

(\$ in millions)

| | Actual FY16 | Actual FY17 | Actual FY18 | Actual FY19 | Actual FY20 |
|--|----------------|----------------|----------------|----------------|----------------|
| CONSOLIDATED STATEMENT OF ACTIVITIES | | | | | |
| Total operating revenues | 8,576 | 9,194 | 10,094 | 11,018 | 11,310 |
| Tuition and fees, net ⁽¹⁾ | 903 | 938 | 1,096 | 1,156 | 1,177 |
| Sponsored programs | 904 | 967 | 1,006 | 1,022 | 1,074 |
| Net patient service revenue | 5,320 | 5,703 | 6,245 | 6,932 | 6,804 |
| Investment income | 439 | 541 | 579 | 676 | 745 |
| Total operating expenses | 8,140 | 8,851 | 9,561 | 10,499 | 10,945 |
| Change in net assets from operating activities | 436 | 343 | 533 | 519 | 365 |
| Nonoperating change in net assets | 585 | 1,392 | 1,794 | 332 | (224) |
| Increase in total net assets | 1,021 | 1,735 | 2,327 | 851 | 141 |
| CONSOLIDATED STATEMENT OF FINANCIAL POSITION HIGHLIGHTS | | | | | |
| Investments, at fair value | 12,262 | 13,977 | 15,734 | 16,499 | 16,870 |
| Property, plant and equipment, net | 6,203 | 6,452 | 7,319 | 8,029 | 8,778 |
| Debt obligations ⁽²⁾ | 2,560 | 2,703 | 3,574 | 3,706 | 4,456 |
| Total assets | 21,183 | 23,083 | 26,415 | 28,079 | 30,413 |
| Total liabilities | 6,671 | 6,835 | 7,841 | 8,655 | 10,847 |
| Total net assets | 14,512 | 16,248 | 18,574 | 19,424 | 19,566 |
| RESEARCH (including ICR) | | | | | |
| Grants, contracts, and similar agreements: | | | | | |
| Federal government sources | 681 | 691 | 701 | 734 | 736 |
| Other | 223 | 276 | 305 | 288 | 338 |
| Total grants, contracts, and similar agreements | 904 | 967 | 1,006 | 1,022 | 1,074 |
| STUDENTS | | | | | |
| ENROLLMENT (FTE) | | | | | |
| Undergraduate | 10,800 | 10,884 | 10,907 | 11,020 | 10,923 |
| Graduate and professional | 11,867 | 11,675 | 11,948 | 12,239 | 12,848 |
| Total fall enrollment | 22,667 | 22,559 | 22,855 | 23,260 | 23,770 |

(1) FY18, FY19, and FY20 tuition and fees, net include room and board revenue (previously included in Sales and services of auxiliary enterprises).

(2) FY16 includes LGH debt obligation FY18 includes UPHS \$600 million new money debt issuances.

CONTENT

02 FY 2020 Financial Review

11 Independent Auditor's Report

12 Consolidated Statements of Financial Position

13 Consolidated Statements of Activities

14 Consolidated Statements of Cash Flows

15 Consolidated Notes to Financial Statements

48 Trustees of the University of Pennsylvania

49 Statutory Officers

UNIVERSITY OF PENNSYLVANIA FINANCIAL OVERVIEW

From the Vice President for Finance and Treasurer

Fiscal Year 2020 presented the University of Pennsylvania with unprecedented challenges in the form of the COVID-19 global pandemic. In response, Penn pivoted quickly to online instruction in March 2020. Faculty redesigned their courses for a virtual environment, students depopulated their on-campus housing and returned home to their families, and staff prepared to begin working from home indefinitely. The University offered comprehensive support across the entire Penn community.

- Penn provided extensive emergency support to financially vulnerable students when Penn depopulated campus in March. Offices across campus partnered to provide funding for food, travel, and at-home internet expenses for hundreds of undergraduate students. Graduate students were eligible for technology grants to support their academic work.
- Penn eliminated the summer savings expectation for all aided undergraduate students in the 2020-2021 academic year in anticipation of students having fewer opportunities to earn money over the summer to put toward their academic expenses.
- Penn launched a comprehensive plan for researchers to begin returning to their laboratories over the summer while observing all necessary public health precautions.
- Penn announced a \$4M emergency fund for employees, third-party contract workers, and small businesses in University City who have been negatively impacted by COVID-19.
- The Perelman School of Medicine established The Center of Research on Coronaviruses and Other Emerging Pathogens, a new center that aims to advance research to better understand the pathology of the coronavirus and,



ultimately, support the development of potential vaccines, diagnostic tools, and effective therapies.

Despite the pandemic, Fiscal Year 2020 was another remarkable year for the University of Pennsylvania with notable achievement across all aspects of Penn Compact 2022 and strong financial results. Among the financial highlights:

Endowment

- Against the backdrop of a volatile year for global equity markets, Penn's AIF returned 3.4%, and total endowment increased by \$228 million to \$14.9 billion.
- Payouts from the endowment provided \$655 million in budgetary support to the University during the fiscal year. Growing steadily, spending distributions from the endowment supported approximately 14% of the University's academic operating budget, up from less than 10% a decade ago.

Financial Performance

- Consolidated operating revenue increased 2.6%, from \$11.0 billion to \$11.3 billion in FY20. Strong operating and non-operating performance contributed to growth in net assets of \$141.4 million, ending the year at a record \$19.6 billion.

Fundraising

- In FY20, Penn's alumni, parents, and loyal supporters contributed \$655 million in new gifts and pledges and \$705 million in cash receipts.
- The W. P. Carey Foundation made a \$125 million gift to the Law School, the largest gift ever to a law school. In recognition of the Foundation's generosity and in honor of the Carey family, the school will be named the University of Pennsylvania Carey Law School.

Students

- The Class of 2024 is comprised of 2,321 students from 67 nations and 50 states.
- Undergraduate debt reduction remains a major goal. Student loan takers in FY20 were one third of the level of loan takers in FY04, a testament to the impact of our institutional grant-based financial aid.
- In addition to continuing its groundbreaking financial aid initiatives for highly aided students through the Penn First Plus program, Penn also enhanced its commitment to middle income families, guaranteeing that those with incomes up to \$140,000 and typical assets will receive financial aid packages that cover at least tuition.

Sustainability

- The University of Pennsylvania has signed a Power Purchase Agreement (PPA) for the creation of a solar power project, moving the University significantly closer to meeting its commitment of a 100% carbon neutral campus by 2042. Expected to be the largest solar power project in the Commonwealth of Pennsylvania, and in higher education, the agreement results in the construction of two new central Pennsylvania solar energy facilities from which Penn will purchase all electricity produced at the sites—equal to about 75% of the total electricity demand of the academic campus and the University of Pennsylvania Health System.

Social Equity, Diversity, and Inclusion

- Charles L. “Chaz” Howard became the University of Pennsylvania's first-ever Vice President for Social Equity and Community, effective August 1,

2020. As Vice President for Social Equity and Community, Dr. Howard will lead programs and initiatives that promote and support communication, collaboration, research and innovative programming within the Penn community that deepen awareness and help to advance the University's mission of fostering social equity, diversity, and inclusion.

Penn Medicine


- The University of Pennsylvania Health System (“UPHS”) marked its 20th consecutive year of positive operating performance with a FY20 operating margin of 3.1%, or \$242.7 million.

Overall, Penn's solid operating performance, fundraising, and investment management, coupled with our manageable capital funding and prudent debt management, have contributed to balance sheet strength that enables continued investment in Penn Compact 2022.

BALANCE SHEET AND NET ASSETS


Total assets grew 8.3% over the prior year to \$30.4 billion while liabilities increased 25.3% to \$10.8 billion. Cash and cash equivalents increased \$742.5 million, or 54.0%, to \$2.1 billion, primarily driven by strong operating performance, the University's \$300 million century bond issuance, the Health System's \$600 million bond issuance, and \$599 million in Medicare advance payments received by the Health System, offset by capital spending on strategic projects.

Net assets totaled \$19.6 billion, an increase of \$141.4 million, or 0.7%, from FY19. Growth in cash, investments, and property, plant, and equipment were partially offset by the new debt and an unfavorable pension adjustment. Since FY16, consolidated net assets have grown by 34.8%, impacted by favorable investment and operating performance, strong fundraising efforts, and UPHS regional expansion.



OPERATING REVENUE


Total operating revenue increased by 2.6%, rising from \$11.0 billion in FY19 to \$11.3 billion in FY20.



Tuition and Fees

Tuition and student fee revenue increased 1.8% over FY19, representing 10.4% of FY20 total operating revenue. This total is net of \$360.9 million in undergraduate and graduate financial aid grants and scholarships, which increased by \$10.9 million, or 3.1%, over the prior fiscal year.


The Penn Compact 2022's mission of Inclusion, Innovation, and Impact continues to be Penn's guiding principle. For more than a decade, Penn has been expanding access to a world-class education for families of all income levels by meeting 100% of a student's demonstrated financial need. To promote inclusion and increased access, Penn provides grant-based undergraduate financial aid packages and adheres to a need-blind admission policy, in which admission decisions are not affected by a student's ability to pay.



Sponsored Programs

Sponsored program revenue, comprised of funding from government and private-sponsored grants and contracts, totaled \$1.1 billion in FY20, an increase of \$52.2 million or 5.1% over the prior fiscal year. Sponsored program revenue represented 9.5% of total operating revenue.

As one of the nation's top research universities, the funding provided to Penn is vital in generating advances in the physical and social sciences, medicine, and other leading-edge fields. Private sector partnering and commercialization of technologies enabled by innovators across the University are making vital contributions to a growing number of COVID-19 diagnostics, therapeutics, vaccines, clinical interventions and technical solutions. Breakthroughs made by Penn faculty members are core components of numerous high-profile product candidates, including multiple leading vaccine candidates for COVID-19.



In FY20, a total of \$884.7 million, or 70.6%, of Sponsored Program awards came from the federal government, Penn's largest source of research funding. Of the federal funding, \$627.3 million, or 70.9%, came from the National Institutes of Health (NIH). The Perelman School of Medicine was among the top three medical schools nationwide in grants awarded by the NIH. Overall, total federal government awards issued to Penn in FY20 increased by \$99 million, or 12.6%.

Industry and foundation awards accounted for \$328.1 million, or 26.2%, of total sponsored program

awards. Other funding sources accounted for \$40.4 million, or 3.2%, of sponsored program awards.

Contributions

Contributions, defined as new gifts and pledges, totaled \$551.8 million in FY20, a \$117.5 million, or 17.6%, decrease from the FY19 total of \$669.4 million. FY20 contributions were comprised of \$244.8 million to restricted endowment, \$215.4 million to support operations, and \$91.6 million toward capital.

Under Council for Advancement and Support of Education reporting standards, during FY20 Penn received 119 gifts of more than \$1 million, with 48 of those coming from first-time donors at that level. Contributions to The Penn Fund increased 9.5% from \$39.8 million in FY19 to \$43.6 million in FY20 and annual giving increased by 4.5% from \$85.9 million to \$89.8 million. Donors established 84 new undergraduate scholarships.

Investment Income

Operating investment income, primarily endowment paid out in accordance with Penn’s spending rule policy, increased by \$69.0 million, or 10.2%, from \$675.9 million in FY19 to \$744.9 million in FY20. The spending rule policy is described in more detail under the Endowment section later in this report.

Other Revenue Sources


Other income increased 29.2% from \$931.5 million in FY19 to \$1.2 billion in FY20. Independent operations decreased 21.1% to \$60.8 million in FY20. Commonwealth appropriations, which predominantly provide support for Penn’s School of Veterinary Medicine, increased 1.8% to \$35.1 million in FY20.

OPERATING EXPENSE

Total operating expenses increased by 4.2%, rising from \$10.5 billion in FY19 to \$10.9 billion in FY20. Compensation and benefits—the combination of salary, wages, and employee fringe benefits—is the largest expense component, representing 57.7% of total operating expenses. Salaries and wages increased 5.8%, from \$4.7 billion in FY19 to \$5.0 billion in FY20. Employee benefits increased 3.7% from FY19 to FY20.

Depreciation and amortization of \$535.0 million, representing 4.9% of total operating expenses, decreased 1.0% from FY19. Interest on indebtedness totaled \$87.8 million, accounting for 0.8% of total operating expenses and decreasing 7.4% from FY19.

Other operating expenses, predominantly purchases of supplies and services, increased 3.5%, from \$3.9 billion in FY19 to \$4.0 billion in FY20, and represented 36.6% of total operating expense. Operating expenses were impacted by increased spending on enterprise system implementations, including the Workday Human Capital Management system, which went live on July 1, 2019, and the Next Generation Student Systems project, with multiple release dates over the next two fiscal years.



CAPITAL EXPENDITURES

Capital expenditures for the Consolidated University increased from \$1.2 billion in FY19 to \$1.4 billion in FY20.

In FY20, capital expenditures for the academic component of the University totaled \$342.9 million, an increase of \$85.2 million, or 33.1% over FY19.

These capital projects represent Penn’s fulfillment of the objectives outlined in Penn Connects 3.0, a land use and urban design campus plan that advances Penn as a premier urban research university. Penn Connects promotes sustainability and development initiatives including reinvestment in existing buildings


and infrastructure, reduction of energy demand, and creation of pedestrian transportation modes with the least amount of environmental impact.

Academic project highlights include:

- Tangen Hall, a Penn Wharton Venture Lab, located at 40th and Sansom Streets will create a focal, iconic, and magnetic 24/7 facility pulsing with student creativity and energy. The facility will include space for: studio-style teaching; co-working and team-based work on specific projects; events; and administrative offices for Wharton Entrepreneurial program. The project was completed in Fall 2020.
- The revitalized Penn Squash Center was completed in FY20. The 25,000 square foot facility was renovated to include twelve courts, including two four-walled glass exhibition courts with ample spectator seating. The design incorporates space for men's and women's team rooms, coach offices, and an entrance lobby.
- The Wharton Academic Research Building, which received Trustee approval in November 2017, will be completed in Winter 2020. In conjunction with the replacement of the substation at 37th Street and Spruce Streets, the five-story, 50,000 square foot building over the substation has office space, collaboration areas, and flat classrooms to alleviate current and future space constraints.
- The design for Pennovation Works Main Lab Building began in Winter 2019. Building on the success of the Pennovation Center, the Pennovation Works Lab Building will renovate the existing four-story Building 227 with wet labs, office/flex space, and amenities including a shared conference room, break room, and kitchenette on each floor. The building will be completed in Fall 2020.
- A significant investment in the University's College House system took place in FY20, including renovations to the Kings Court/English House and Du Bois College House and design for a major multi-year renovation of the Quadrangle.

- Construction continues on New College House West, a new 250,000 square foot undergraduate residential building along 40th Street between Walnut and Locust Streets. The estimated completion date is Summer 2021.

As described later in this report, UPHS invested \$1.1 billion in capital projects, highlighted by their New Patient Pavilion to be completed in 2021.



Penn's Climate Action Plan

In October 2019, Penn announced its Climate & Sustainability Action Plan 3.0, outlining the University's goals for improved environmental performance for the next five years. Since the launch of Penn's sustainability efforts in 2009, Penn has achieved a reduction in building-related emissions of over 27%. The Century Bond program, established in 2012, has been used to upgrade lighting in 45 buildings and for comprehensive HVAC replacements across nine buildings, and continues to support energy projects across campus.

DEBT

Consolidated debt totaled \$4.5 billion in FY20, an increase of \$749.7 million, or 20.2%, from FY19. On August 1, 2019, the University issued \$300 million in century bonds at a then record-setting interest rate of 3.61%. Penn will use the newly borrowed funds for general corporate purposes, including the financing or refinancing of capital projects.


On December 5, 2019, UPHS issued revenue bonds with an aggregate principal amount of \$535 million (for net proceeds of \$600 million) with proceeds used to fund capital projects, including the New Patient Pavilion. Penn's credit rating from Standard and Poor's and Moody's Investors Services is

AA+/Aa1 for the University and AA/Aa3 for UPHS.

UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM


UPHS includes six major hospitals – the Hospital of the University of Pennsylvania (HUP), Penn Presbyterian Medical Center, Pennsylvania Hospital, Chester County Hospital, Lancaster General Hospital, and the University Medical Center of Princeton. UPHS is recognized internationally as a leading healthcare system with the faculty-based Clinical Practices of the University of Pennsylvania, home care and hospice services, and physician practices and facilities in communities throughout the Delaware Valley. The University's Perelman School of Medicine joins with UPHS as a part of Penn Medicine, a world-renowned academic medical center with hospitals ranked among the highest in the nation by U.S. News and World Report.

UPHS marked its 20th consecutive year of positive operating performance with a FY20 UPHS operating margin of 3.1%, or \$242.7 million.



Total FY20 UPHS operating revenues were \$7.8 billion, reflecting a 2.8% increase over the prior year. Patient services revenue, the largest revenue component at 60.2% share of total Consolidated University operating revenue, decreased by 1.9% from \$6.9 billion in FY19 to \$6.8 billion in FY20. The decrease was primarily attributed to COVID-19 and the disruption to the nation's healthcare systems.

UPHS Adjusted and Inpatient Admissions
(Adjusted for outpatient activity)



UPHS operating expenses for FY20 were \$7.6 billion, an increase of 5.7% over the prior year. The decrease in unrestricted net assets for UPHS, including non-operating revenue and realized/unrealized gain on investments, totaled \$135.8 million for FY20, a decrease of \$232.3 million from prior year. The decrease was attributable to the negative impact to operations from the COVID-19 pandemic and an unfavorable pension adjustment.

FY20 Days Cash on Hand was 258 days, an increase of 35 days from the prior year primarily due to issuance of the Series A 2019 bonds at a par value of \$535 million (for net proceeds of \$600 million) and \$599 million in advance payments from the Centers for Medicare and Medicaid Services (CMS) Accelerated and Advanced Payments Program. Debt-to-Capitalization increased to 35.4% in FY20 from 30.8% in FY19.

UPHS capital expenditures for FY20 were \$1.06 billion, an increase of \$79.7 million over the prior year. The increase in expenditures was primarily attributable to strategic projects including the New Patient Pavilion at HUP, patient towers at Chester County, and Radnor master plan.

The \$1.5 billion New Patient Pavilion, opening in 2021, will support Penn's world-renowned researchers, clinicians, and faculty, and will include 500 private patient rooms, 50 operating and procedure rooms, and an Emergency Department.

ENDOWMENT


The University of Pennsylvania's endowment totaled \$14.9 billion as of June 30, 2020, an increase of \$228 million over the past year. Penn's endowment

is comprised of over 7,000 funds benefiting the University's schools, centers, and Health System.

The vast majority of Penn's endowment is invested in the Associated Investments Fund (AIF), a pooled investment vehicle in which the many individual endowments and trusts hold shares or units. An Investment Board appointed by the Trustees of the University oversees the investment of the AIF. The University's Office of Investments is responsible for the day-to-day management of the AIF and implements the policies approved by the Investment Board.

The purpose of Penn's endowment is to provide stable and perpetual support for the mission and programs of the University. Achieving this objective requires an investment and spending program that supports intergenerational equity. The AIF must provide substantial and stable spending today, but it also must preserve purchasing power in order to provide comparable resources to future generations. Penn seeks to resolve the tension between these competing needs by investing in a diversified, equity-oriented portfolio and by adhering to a disciplined spending rule that smooths the impact of changes in AIF value on the operating budget.

**Endowment Growth and AIF Payout
(\$ in millions)**




The University's endowment spending policy balances the objectives of maximizing budgetary support to endowed programs and maintaining purchasing power of the endowment into perpetuity. The actual payout in any given year is determined by a formula designed to smooth the impact of short-term changes in the endowment's value on spending distributions. The spending rule target payout for

fiscal 2020 was based on the sum of: (i) 70% of the prior fiscal year distribution adjusted by an inflation factor; and (ii) 30% of the lagged fiscal year-end fair value of the AIF, multiplied by Penn's 5.0% target spending rate.

Payouts from the endowment provided \$655 million in budgetary support to the University during the fiscal year. Spending support from the AIF for University operations has grown by an annualized 10.1% over the last decade and now represents approximately 14.4% of the University's academic operating budget, up from less than 9.7% a decade ago.

The endowment supports a wide range of purposes across the institution, with the significant majority of funds dedicated to instructional use and student financial aid.

**Endowment by Purpose
As of June 30, 2020**




AIF INVESTMENT PROGRAM

Penn builds its investment program around several simple tenets. First, in order to achieve the high returns necessary to preserve purchasing power after spending, the AIF is invested with a strong equity orientation. With the exception of fixed income, Penn expects that all asset classes in which it invests can earn equity-like returns over long periods of time. Second, Penn builds a portfolio that is diversified across different fundamental drivers of return. The University focuses on areas with the greatest inefficiencies across asset classes, strategies, and geographies. Finally, Penn capitalizes upon the perpetual nature of the University to invest with a long time horizon, creating a significant advantage relative to the many market participants who must focus on near-term certainty instead of long-term attractiveness when evaluating investments.

AIF Asset Allocation

As of June 30, 2020



Penn has established a Strategic Asset Allocation (SAA), with investment class target ranges which represent reasonable allocation ranges for the portfolio in a normal environment. Portfolios within these ranges reflect the broad equity orientation and diversification that Penn seeks. The SAA guidelines consist of ranges rather than point targets to reflect the impossibility of knowing the future investment opportunity set facing the University. As the portfolio evolves towards the SAA ranges, Penn uses an Interim Policy Portfolio (IPP) to guide asset allocation over shorter periods.

Penn revisits its asset allocation ranges and targets periodically to ensure that they appropriately reflect both the University's long-term investment needs and the opportunity set facing Penn. The most recent review occurred in June 2020.

The AIF portfolio includes investments in illiquid funds, some of which require Penn to make capital commitments that will be drawn down and invested over a period of time. As of June 30, 2020, the AIF had \$3.3 billion in outstanding commitments to various limited partnerships. The AIF maintains a conservative liquidity profile that can accommodate these commitments in both normal environments and periods of market stress or dislocation.


AIF PERFORMANCE

The AIF returned 3.4% in fiscal 2020, increasing by \$578 million to a total value of \$14.2 billion after spending, gifts, and other transfers. The total

endowment ended the year at \$14.9 billion, an increase of \$228 million.

Against the backdrop of a volatile year for global markets as a result of COVID-19, most of Penn's equity-oriented asset classes produced positive returns. Outperformance relative to Penn's composite benchmark (a blend of asset class benchmarks) was driven by notable relative performance in the global equities and absolute return portfolios.

Over longer periods, Penn's performance has consistently outpaced the composite benchmark. Importantly, Penn's long-term performance has enabled the AIF to exceed its goal of maintaining purchasing power after spending distributions.



Future Outlook

Looking ahead to Fiscal Year 2021, Penn will build upon the many achievements of FY20 as we support The Penn Compact 2022's principles of Inclusion, Innovation, and Impact. With the guidance of our distinguished Board of Trustees, overwhelming generosity of our donors, and the commitment of our talented students, esteemed faculty, and dedicated staff, we are well-positioned for continued success in FY21, despite the challenges presented by the pandemic.

MaryFrances McCourt

Vice President for Finance and Treasurer



“Tell me and I forget, teach me and I may remember, involve me and I learn.”



Report of Independent Auditors

To the Trustees of the University of Pennsylvania:

We have audited the accompanying consolidated financial statements of the University of Pennsylvania (the "University"), which comprise the consolidated statements of financial position as of June 30, 2020 and 2019, and the related consolidated statements of activities and of cash flows for the years then ended.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on the consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on our judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the University's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the University of Pennsylvania as of June 30, 2020 and 2019, and its changes in net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Emphasis of Matter

As discussed in Note 1 to the consolidated financial statements, the University changed the manner in which it accounts for leases. Our opinion is not modified with respect to this matter.

A handwritten signature in dark ink that reads "PricewaterhouseCoopers LLP".

October 7, 2020

.....
PricewaterhouseCoopers LLP, Two Commerce Square, Suite 1800, 2001 Market Street, Philadelphia, PA 19013-7042
T: (267) 330 - 3000, F: (267) 330 - 3300, www.pwc.com/us

Consolidated Statements of Financial Position

University of Pennsylvania

(in thousands)

| | June 30, | |
|--|---------------|---------------|
| | 2020 | 2019 |
| Assets | | |
| Cash and cash equivalents | \$ 2,117,979 | \$ 1,375,469 |
| Accounts receivable, net | 507,039 | 398,058 |
| Patient receivables, net | 726,081 | 830,935 |
| Contributions receivable, net | 478,150 | 488,450 |
| Loans receivable, net | 63,398 | 72,362 |
| Other assets | 872,383 | 385,798 |
| Investments, at fair value | 16,870,116 | 16,499,386 |
| Property, plant and equipment, net | 8,778,085 | 8,028,992 |
| Total assets | \$ 30,413,231 | \$ 28,079,450 |
| Liabilities | | |
| Accounts payable | \$ 313,884 | \$ 346,986 |
| Accrued expenses and other liabilities | 3,646,811 | 2,495,808 |
| Deferred income | 189,920 | 192,302 |
| Deposits, advances and agency funds | 220,114 | 190,078 |
| Federal student loan advances | 51,822 | 71,265 |
| Accrued retirement benefits | 1,968,251 | 1,651,685 |
| Debt obligations | 4,456,160 | 3,706,493 |
| Total liabilities | 10,846,962 | 8,654,617 |
| Net assets | | |
| Without donor restrictions | 11,366,361 | 11,392,252 |
| With donor restrictions | 8,199,908 | 8,032,581 |
| Total net assets | 19,566,269 | 19,424,833 |
| Total liabilities and net assets | \$ 30,413,231 | \$ 28,079,450 |

The accompanying notes are an integral part of these consolidated financial statements.

Consolidated Statements of Activities

University of Pennsylvania

for the years ended June 30, 2020 and 2019

(in thousands)

| | 2020 | 2019 |
|---|-----------------|----------------|
| <u>Without donor restrictions</u> | | |
| Revenue and other support: | | |
| Tuition and fees, net | \$ 1,176,737 | \$ 1,155,894 |
| Commonwealth appropriations | 35,144 | 34,518 |
| Sponsored programs | 1,074,494 | 1,022,338 |
| Contributions and donor support | 210,894 | 188,805 |
| Investment income | 744,911 | 675,865 |
| Net patient service revenue | 6,803,782 | 6,932,160 |
| Other income | 1,203,185 | 931,484 |
| Independent operations | 60,819 | 77,047 |
| | 11,309,966 | 11,018,111 |
| Expenses: | | |
| Compensation and benefits | 6,313,668 | 5,991,191 |
| Depreciation and amortization | 535,003 | 540,235 |
| Interest on indebtedness | 87,760 | 94,810 |
| Other operating expenses | 4,008,255 | 3,872,702 |
| | 10,944,686 | 10,498,938 |
| Increase in net assets from operations | 365,280 | 519,173 |
| Nonoperating activities: | | |
| Return on investments, net of amounts classified as operating revenue | (114,855) | 103,711 |
| Pension, OPEB and other, net | (374,803) | (426,535) |
| Contributions and donor support for capital related activities | 98,487 | 42,911 |
| Total nonoperating activities | (391,171) | (279,913) |
| (Decrease) increase in net assets without donor restrictions | (25,891) | 239,260 |
| <u>With donor restrictions</u> | | |
| Contributions | 478,490 | 598,622 |
| Return on investments, net | 231,372 | 464,755 |
| Net assets released from restrictions | (542,535) | (451,770) |
| Increase in net assets with donor restrictions | 167,327 | 611,607 |
| Increase in total net assets | 141,436 | 850,867 |
| Net assets, beginning of year | 19,424,833 | 18,573,966 |
| Net assets, end of year | \$ 19,566,269 | \$ 19,424,833 |

The accompanying notes are an integral part of these consolidated financial statements.

Consolidated Statements of Cash Flows

University of Pennsylvania

For the years ended June 30, 2020 and 2019

(in thousands)

| | 2020 | 2019 |
|--|--------------|--------------|
| Cash flows from operating activities: | | |
| Increase in total net assets | \$ 141,436 | \$ 850,867 |
| Adjustment to reconcile increase in total net assets to net cash provided by operating activities: | | |
| Depreciation and amortization | 516,878 | 521,795 |
| Provision for bad debts | 7,925 | 8,040 |
| Gain on investments, net | (372,476) | (739,519) |
| Loss (gain) on disposal of plant, property and equipment | 1,824 | (10,915) |
| Donated equipment | - | (531) |
| Receipt of contributed securities | (134,329) | (75,188) |
| Proceeds from contributed securities | 26,350 | 22,816 |
| Receipt of contributions designated for the acquisition of long-lived assets and long-term investment | (231,406) | (213,867) |
| Pension, OPEB and other, net | 374,803 | 426,535 |
| Changes in operating assets and liabilities: | | |
| Patient, accounts and loans receivable | (3,700) | (17,451) |
| Contributions receivable | 10,878 | (209,992) |
| Other assets | (49,605) | (27,718) |
| Accounts payable, accrued expenses and accrued retirement benefits | 685,623 | 118,862 |
| Deposits, advances and agency funds | 30,310 | 19,167 |
| Deferred income | (2,382) | (14,134) |
| Net cash provided by operating activities | 1,002,129 | 658,767 |
| Cash flows from investing activities: | | |
| Purchase of investments | (16,043,267) | (13,267,225) |
| Proceeds from sale of investments | 16,168,730 | 13,369,735 |
| Purchase of property, plant and equipment | (1,397,560) | (1,232,647) |
| Net cash used by investing activities | (1,272,097) | (1,130,137) |
| Cash flows from financing activities: | | |
| Proceeds from contributions received designated for the acquisition of long-lived assets and long-term investment | 231,407 | 213,867 |
| Proceeds from contributed securities received designated for the acquisition of long-lived assets and long-term investment | 107,643 | 51,913 |
| Federal student loan advances | (19,443) | 2,579 |
| Repayment of debt obligations | (598,091) | (139,692) |
| Proceeds from issuances of debt obligations | 1,290,962 | 287,000 |
| Net cash provided by financing activities | 1,012,478 | 415,667 |
| Net increase (decrease) in cash and cash equivalents | 742,510 | (55,703) |
| Cash and cash equivalents, beginning of year | 1,375,469 | 1,431,172 |
| Cash and cash equivalents, end of year | \$ 2,117,979 | \$ 1,375,469 |
| Supplemental disclosure of cash flow information: | | |
| Cash paid for interest, net of amounts capitalized | \$ 83,526 | \$ 95,392 |
| Contributed securities received | 134,329 | 75,188 |
| (Decrease) increase in accrued plant, property and equipment | (53,778) | 51,392 |
| Operating cash flows for operating leases | 61,093 | - |
| Right-of-use assets obtained in exchange for lease liabilities | 497,406 | - |

The accompanying notes are an integral part of these consolidated financial statements.

1. Significant Accounting Policies

Organization

The University of Pennsylvania (“University”), located in Philadelphia, Pennsylvania, is an independent, nonsectarian, not-for-profit institution of higher learning founded in 1740. The University Academic Component (“Academic Component”) provides educational services, primarily for students at the undergraduate, graduate, professional and postdoctoral levels and performs research, training and other services under grants, contracts and similar agreements with sponsoring organizations, primarily departments and agencies of the United States Government. The University also operates an integrated health care delivery system, the University of Pennsylvania Health System (“UPHS”). The University is a tax-exempt organization under Section 501(c)(3) of the Internal Revenue Code.

Basis of Presentation

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include the accounts of the University and its subsidiaries over which the University has a controlling financial interest or exercises control. All material transactions between the University and its subsidiaries are eliminated in consolidation. Investments in subsidiaries over which the University has the ability to exercise significant influence are reported using the equity method of accounting. Other investments in subsidiaries are reported using the measurement alternative – at cost adjusted for impairment, if any, unless an observable transaction for an identical or similar security occurs.

The net assets of the University are classified and reported as follows:

Without donor restrictions – includes net assets that are not subject to donor-imposed restrictions.

With donor restrictions – includes net assets that are (i) subject to legal or donor-imposed restrictions that will be met by actions of the University and/or the passage of time, and (ii) the original values of donor restricted net assets, the use of which is limited to investment and can only be appropriated for expenditure by the University in accordance with the Pennsylvania Uniform Principal and Income Act (Pennsylvania Act).

Expenses are reported as a decrease in net assets without donor restrictions. Gains and losses on investments are reported as increases or decreases in net assets without donor restrictions unless their use is restricted by explicit donor stipulation or by law. Donor-restricted resources intended for the acquisition or construction of long-lived assets are initially reported as net assets with donor restrictions and released from restrictions to net assets without donor restrictions when the asset is placed in service or in accordance with donor-specified terms.

Expirations of restrictions on contributions and investment income, reported as Net assets released from restrictions, and the corresponding amounts are included in the Consolidated Statements of Activities as follows (in thousands):

| Net Assets Without Donor Restrictions | 2020 | 2019 |
|--|--------------|--------------|
| Contributions and donor support | \$ 137,572 | \$ 118,068 |
| Investment income | 306,476 | 290,791 |
| Contributions and donor support for capital related activities | 98,487 | 42,911 |
| Net assets released from restrictions | \$ 542,535 | \$ 451,770 |
| Net Assets With Donor Restrictions | 2020 | 2019 |
| Net assets released from restrictions | \$ (542,535) | \$ (451,770) |

Gains or losses associated with investment activities are included in Return on investments, net. Gains or losses associated with property, plant and equipment disposals are included in Other income or Other operating expenses, respectively.

Consolidated Notes to Financial Statements

Gains or losses associated with all other activities, such as debt retirements and pension and postretirement plan actuarial valuation adjustments, are reported in Pension, Other post-retirement employee benefits (OPEB) and other, net.

Fair Value

The University values certain financial and non-financial assets and liabilities by applying the FASB pronouncement on Fair Value Measurements. The pronouncement defines fair value and establishes a framework for measuring fair value that includes a hierarchy that categorizes and prioritizes the sources used to measure and disclose fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The hierarchy is broken down into three levels based on inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the University as follows:

Level 1: Unadjusted quoted market prices in active markets for identical assets or liabilities.

Level 2: Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable.

Level 3: Unobservable inputs for the asset or liability.

Inputs broadly refer to the assumptions that market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, specific and broad credit data, liquidity statistics and other factors. The University is required by the pronouncement to maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3). The University considers observable data to be that market data which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary and provided by independent sources that are actively involved in the relevant market. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to the University's perceived risk of that instrument.

Assets and liabilities are disclosed in the Consolidated Notes to Financial Statements within the hierarchy based on the lowest (or least observable) input that is significant to the measurement. The University's assessment of the significance of an input requires judgment, which may affect the valuation and categorization within the fair value hierarchy. The fair value of assets and liabilities using Level 3 inputs are generally determined by using pricing models or discounted cash flow methods, which all require significant management judgment or estimation.

As a practical expedient, the University is permitted to estimate the fair value of an investment in an investment company at the measurement date using the reported net asset value (NAV). Adjustment is required if the University expects to sell the investment at a value other than NAV or if the NAV is not calculated in accordance with U.S. GAAP. The University holds investments in its portfolio which are generally valued based on the most current NAV. This amount represents fair value of these investments at June 30, 2020 and 2019. Investments reported at NAV, as a practical expedient, are not included within levels 1, 2, or 3 in the fair value hierarchy.

The University performs additional procedures, including due diligence reviews, on its investments in investment companies and other procedures with respect to the capital account or NAV provided to ensure conformity with US GAAP. The University has assessed factors including, but not limited to, managers' compliance with the *Fair Value Measurement* standard, price transparency and valuation procedures in place.

Cash and Cash Equivalents

Cash equivalents include liquid investments available for current operations with maturities of three months or less when purchased and are carried at cost which approximates fair value. All short-term, highly liquid investments, otherwise

qualifying as cash equivalents or restricted cash equivalents, included in the University's investments are treated as Investments, at fair value and are therefore excluded from Cash and cash equivalents in the Statements of Cash Flows.

Investments, at Fair Value

The majority of the University's investments are held in the Associated Investments Fund (AIF). The AIF is invested in accordance with the investment policies set out by an Investment Board which has been appointed by the Trustees of the University of Pennsylvania (the Trustees). The Office of Investments is responsible for the day-to-day management of the AIF including identifying, selecting and monitoring a variety of external investment managers to implement the strategic asset allocation set forth by the Investment Board. The AIF may include marketable and not readily marketable securities that it intends to hold for an indefinite period of time. The University also holds other investments which are not invested in the AIF due to various restrictions. The majority of these investments are in highly liquid short-term and equity type investments. Changes in the fair value of investments are reported in Return on investments, net in the Consolidated Statements of Activities. The following is a summary of the investments held in the AIF by asset allocation as well as investment risk:

Short-Term

Short-term investments include cash equivalents and fixed income investments with maturities of less than one year. Short-term investments are valued using observable market data and are categorized as Level 1 based on quoted market prices in active markets. The majority of these short-term investments are held in a US Treasury money market account.

Equity

Equity investments consist of direct holdings of public securities in managed accounts as well as mutual funds and private funds. The securities held in managed accounts, along with mutual funds, are generally valued based on quoted market prices in active markets obtained from exchange or dealer markets for identical assets, and are accordingly categorized as Level 1. Private funds are valued at NAV.

Debt

Debt investments consist of direct holdings of securities in managed accounts and private funds. Securities such as US Treasuries, held in managed accounts, are valued based on quoted market prices in active markets and are categorized as Level 1. Securities such as corporate and sovereign bonds, also held in managed accounts, are valued based on quoted market prices or dealer or broker quotations and are categorized as Level 2 or in the cases where inputs are unobservable as Level 3. Private funds are valued at NAV.

Absolute Return

Absolute return investments are made up of allocations to private funds. The fund managers of these private funds invest in a variety of securities, based on the strategy of the fund, which may or may not be quoted in an active market. Private funds are valued at NAV.

Real Estate

Investments in real estate are primarily in the form of private funds. The fund managers of these private funds primarily invest in investments for which there is no readily determinable market value. The fund managers may value the underlying investments based on an appraised value, discounted cash flow, industry comparables or some other method. Private funds are valued at NAV.

Private Equity

Investments in private equity are in the form of close-ended private funds. The fund managers primarily invest in investments for which there is no readily determinable market value. The fund managers may value the underlying private investments based on an appraised value, discounted cash flow, industry comparables or some other method. These private fund investments are valued at NAV.

Natural Resources

Investments in natural resources are made up of private funds and securities in managed accounts. The fund managers of these private funds primarily invest in investments for which there is no readily determinable market value. The fund managers may value the underlying investments based on an appraised value, discounted cash flow, industry comparables or some other method. Private funds are valued at NAV. The securities held in managed accounts are generally valued based on quoted market prices in active markets obtained from exchange or dealer markets for identical assets, and are accordingly categorized as Level 1.

Derivatives

The University, in the normal course of business, utilizes derivative financial instruments in connection with its investment activity. Derivatives utilized by the University include futures, options, swaps and forward currency contracts and are reflected at fair value following the definition of Level 1 and 2 assets and liabilities as previously described. Investments in derivative contracts are subject to foreign exchange and equity price risks that can result in a loss of all or part of an investment. In addition, the University is also subject to additional counterparty risk should its counterparties fail to meet the terms of their contracts.

Investment Risks

The University's investing activities expose it to a variety of risks including market, credit and liquidity risks. The University attempts to identify, measure and monitor risk through various mechanisms including risk management strategies and credit policies.

Market risk is the potential for changes in the fair value of the University's investment portfolio. Commonly used categories of market risk include currency risk (exposure to exchange rate differences between functional currency relative to other foreign currencies), interest rate risk (changes to prevailing interest rates or changes in expectations of futures rates) and price risk (changes in market value other than those related to currency or interest rate risk, including the use of NAV provided).

Credit risk is the risk that one party to a financial investment will cause a financial loss for the other party by failing to discharge an obligation (counterparty risk).

Liquidity risk is the risk that the University will not be able to meet its obligations associated with financial liabilities.

Endowment

The University's endowment consists of 6,909 donor-restricted endowment funds and 928 quasi-endowment funds established by management for a variety of purposes. The University reports all endowment investments at fair value. The majority of the endowment funds of the University have been pooled in the University's AIF. The endowment funds not pooled in the AIF are primarily invested in equities and bonds.

The Commonwealth of Pennsylvania has not adopted the Uniform Management of Institutional Funds Act (UMIFA) or the Uniform Prudent Management of Institutional Funds Act (UPMIFA). Rather, the Pennsylvania Act governs the investment, use and management of the University's endowment funds.

The Pennsylvania Act does not require the preservation of the fair value of a donor's original gift as of the gift date of a donor-restricted endowment fund, absent explicit donor stipulations to the contrary. However, based on its interpretation of the Pennsylvania Act and relevant accounting literature, the University classifies the following as net assets with donor restrictions for reporting purposes: (i) the original value of donated assets required to be invested in perpetuity; (ii) the original value of subsequent donated assets required to be invested in perpetuity; (iii) accumulations to the donated assets invested in perpetuity made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund; and (iv) donated assets and accumulations that are subject to legal or donor-imposed restrictions that will be met by actions of the University and/or the passage of time. The Pennsylvania Act allows a nonprofit to elect to appropriate for expenditure between 2% and 7% of the endowment fair value, determined at least annually and averaged over a period of three or more preceding years, including funds whose fair value is less than the original donated value.

In accordance with the Pennsylvania Act, the University has elected to adopt and follow an investment policy seeking a total return for the investments held by the AIF, whether the return is derived from appreciation of capital or earnings and distributions with respect to capital or both. The endowment spending policy which the Board of Trustees has elected to govern the expenditure of funds invested in the AIF, including funds whose fair value is less than the original donated value, is designed to manage annual spending levels and is independent of the cash yield and appreciation of investments for the year. For fiscal year 2020, the spending rule target payout was based on the sum of: (i) 70% of the prior fiscal year distribution adjusted by an inflation factor; and (ii) 30% of the prior fiscal year-end fair value of the AIF, lagged one year, multiplied by 5.0% for all funds. The payout or allocation to operations exceeded actual income, net of expenses, by \$654,691,000 in 2020 and by \$577,039,000 in 2019.

Property, Plant and Equipment

Property, plant and equipment (PPE) is reported net of related depreciation. Donated PPE is reported based on estimated fair value at the date of acquisition. All other PPE is reported at cost. Depreciation is computed on the straight-line method over the estimated useful lives of the assets or the shorter of the lease term or estimated useful life of the asset for capital lease assets. Contributions of library materials, as well as rare books and other collectibles, are not recorded for financial statement presentation, while purchases are recorded as Other operating expenses on the Consolidated Statement of Activities in the period acquired.

Split-Interest Agreements

The University's split-interest agreements with donors consist of irrevocable charitable remainder trusts, charitable gift annuities, pooled income funds, perpetual trusts and charitable lead trusts. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements.

The University recognizes assets contributed to charitable remainder trusts, charitable gift annuities and pooled income funds, where it serves as trustee, at fair value, recognizes a liability to the beneficiaries based on the present value of the estimated future payments to beneficiaries to be made over the estimated remaining life of those beneficiaries using current market rates at the date of the contribution, and recognizes the difference as contribution revenue. Subsequently, the trust assets, invested in equity and debt securities, are measured at fair value at quoted market prices, and are categorized as Level 1, with the changes reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. Liabilities to beneficiaries are revalued based on current market rates, and are categorized as Level 2, with the changes reported as an adjustment to Accrued expense and other liabilities on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities.

Charitable remainder trust assets, where the University does not serve as trustee, are initially valued using the current fair value of the underlying assets, using observable market inputs based on its beneficial interest in the trust, discounted to a single present value using current market rates at the date of the contribution. The initially contributed assets are

categorized as Level 3, and reported as Investments, at fair value on the Consolidated Statements of Financial Position and Contribution revenue on the Consolidated Statements of Activities. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. The primary unobservable input used in the fair value measurement of the charitable remainder trust assets is the discount rate. Significant fluctuation in the discount rates utilized in this calculation could result in a material change in fair value.

Perpetual trust assets are initially valued at the current fair value of the underlying assets using observable market inputs based on its beneficial interest in the trust. The initially contributed assets are categorized as Level 3 and are reported as Investments, at fair value on the Consolidated Statements of Financial Position and as Contribution revenue on the Consolidated Statements of Activities. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. The primary unobservable inputs used in the fair value measurement of the perpetual trust assets are the underlying securities held by the trust. Significant fluctuation in the market value of these underlying securities could result in a material change in fair value.

The University reports charitable lead trust assets by discounting future cash flows using current market rates at the measurement date, matched to the payment period of the agreement. The initially contributed assets are categorized as Level 3, and reported as Investments, at fair value on the Consolidated Statements of Financial Position and as Contribution revenue on the Consolidated Statements of Activities. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to Investments, at fair value on the Consolidated Statements of Financial Position and Return on investments, net on the Consolidated Statements of Activities. The primary unobservable input used in the fair value measurement of the charitable lead trust assets is the discount rate. Significant fluctuation in the discount rates utilized in this calculation could result in a material change in fair value.

Income Taxes

The University is a tax exempt organization under Section 501(c)(3) of the Internal Revenue Code. Most of its activities and income are related to its exempt purposes and are exempt from federal and state income taxes. None of its activities and income is subject to Pennsylvania income tax. Unrelated activities and income are subject to federal "Unrelated Business Income Tax."

The University regularly evaluates its tax position and does not believe it has any uncertain tax positions that require disclosure or adjustment to the consolidated financial statements.

Tuition and Fees

Tuition and fees includes tuition, room and board, and other student fees which are recognized as revenue over time during the fiscal year in which the related academic services are rendered. Tuition and fees received in advance of services to be rendered are reported as Deferred income on the Consolidated Statements of Financial Position. The University maintains a policy of offering qualified applicants admission to the University without regard to financial circumstance, as well as meeting in full the demonstrated financial need of those admitted. Tuition and fees have been reduced by certain grants and scholarships in the amount of \$360,863,000 in 2020 and \$349,981,000 in 2019.

Sponsored Programs

Sponsored programs includes revenue from exchange and conditional non-exchange agreements with governments, foundations and private sources generally for research activities. Revenue from exchange agreements is generally recognized at a point in time when performance obligations are met, and revenue from conditional non-exchange agreements is generally recognized as the related costs are incurred. Non-exchange agreements are considered conditional if the terms of the agreement include both a right of return/release of assets received/promised and a barrier. These agreements become unconditional as barriers are met. At June 30, 2020, the University has unrecorded conditional agreements of \$2,164,163,000. In 2020 and 2019, sponsored programs revenue earned from governmental sources totaled

\$753,901,000 and \$753,118,000, respectively. Indirect costs recovered on federally-sponsored programs are generally based on predetermined reimbursement rates which are stated as a percentage and distributed based on the modified total direct costs incurred. The University negotiates its federal indirect rate with its cognizant federal agency. Indirect costs recovered on all other grants and contracts are based on rates negotiated with the respective sponsors. Funds received for sponsored research activity are subject to audit. Based upon information currently available, management believes that any liability resulting from such audits will not materially affect the financial position or operations of the University.

Contributions

Contributions are revenues from unconditional non-exchange agreements with private sources and foundations. Contributions are recognized in the period received and reported as increases in the appropriate net asset category based on the presence or absence of donor-imposed restrictions. Non-exchange agreements are considered conditional if the terms of the agreement include both a right of return/release of assets received/promised and a barrier. These agreements become unconditional as barriers are met. Contributions and donor support without donor restrictions also includes net assets released as a result of corresponding expenditures which met donor-imposed restrictions. Contributions designated for the acquisition of long-lived assets and long-term investment are reported in Nonoperating activities.

The University reports unconditional pledges at fair value by discounting future cash flows using current market rates at the measurement date, ranging from 0.53% to 1.93%, matched to the payment period of the agreement, and accordingly categorizes these assets as Level 3. The primary unobservable input used in the fair value measurement of the University's Contributions receivable is the discount rate. Significant fluctuation in the discount rates utilized in this calculation could result in a material change.

Net Patient Service Revenue

Net patient service revenue is derived from contracts with patients of UPHS in which its performance obligation is to provide health care services. Net patient service revenue is recorded over time during the period these performance obligations are satisfied and at the determined transaction price, which represents the estimated net realizable amounts due from patients, third-party payers and others for health care services rendered. Estimated net realizable amounts represent amounts due, net of implicit and explicit price concessions. Implicit price concessions are based on management's assessment of expected net collections considering economic conditions, historical experience, trends in health care coverage and other collection indicators. After satisfaction of amounts due from insurance and reasonable efforts to collect from patients have been exhausted, UPHS follows established guidelines for placing certain past-due patient balances with collection agencies, subject to terms of certain restrictions on collection efforts as determined by UPHS. Patient receivables are written off after collection efforts have been followed in accordance with UPHS' policy. Certain revenue received from third-party payers is subject to audit and retroactive adjustment. Any changes in estimates under these contracts are recorded in operations currently.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

COVID-19

In January 2020, the World Health Organization declared the novel strain of coronavirus ("COVID-19") a Public Health Emergency of International Concern. The COVID-19 pandemic has caused disruptions to our nation's healthcare and higher education systems, including the University's. Such disruptions included reductions in availability of staffing and in the availability of personal protective equipment to prevent spread of the disease during patient treatment. Generally, elective procedures were postponed by physicians and acute care facilities to prepare for the expected volume of COVID-

19 patients and reduce the risk of exposure to COVID-19. Other negatively impacted areas include, but are not limited to, student enrollment, housing and dining revenues, research, faculty, staff & student travel, investment performance, philanthropy and increased financial need of students. The University is monitoring legislative developments, including future relief funding opportunities, and directives from federal, state, and local officials to determine additional precautions and procedures that may need to be implemented.

In response, on March 27, 2020 the Federal Government passed the Coronavirus Aid, Relief, and Economic Stimulus Act (CARES Act) which made funds available to UPHS and the Academic Component through various provisions of the legislation. As of June 30, 2020, UPHS received CARES Act provider relief funding of \$213,160,000 reported as Other income on the Consolidated Statements of Activities. In addition, UPHS received \$599,498,000 in advanced payments from the Centers for Medicare and Medicaid Services (CMS) Accelerated and Advanced Payments Program reported as Accrued expense and other liabilities on the Consolidated Statements of Financial Position. Furthermore, the CARES Act allowed employers to defer the deposits and payments of the employer's share of the Social Security taxes. As of June 30, 2020, \$34,731,000 and \$27,314,000 were deferred and reported as Accrued expense and other liabilities on the Consolidated Statements of Financial Position, for UPHS and the Academic Component, respectively. UPHS recognized revenue related to the CARES Act funding based on information available at June 30, 2020 based upon laws and regulations governing the funding as well as interpretations issued by the Department of Health and Human Services (HHS). In September 2020, HHS issued new reporting requirements for the CARES Act funding. Due to these new reporting requirements there is at least a reasonable possibility that amounts recorded under CARES Act funding may change in future periods.

Recent Authoritative Pronouncements

Periodically, the Financial Accounting Standards Board (FASB) issues updates to the Accounting Standards Codification (ASC) which impacts the University's financial reporting and related disclosures. The paragraphs which follow summarize a number of relevant updates.

In February 2016, the FASB issued a standard on Leases. This standard requires lessees to recognize assets and liabilities for the rights and obligations created by leases. The recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily depends on its classification as a finance or operating lease. The University adopted this standard for fiscal year 2020 on a modified retrospective basis, the impact of which is noted in the accompanying Leases footnote.

In November 2016, the FASB issued a standard on Restricted Cash. This standard requires the Consolidated Statements of Cash Flows explain the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents during a fiscal year. It is also required that this total be reconciled to the amounts reported on the Consolidated Statements of Financial Position and that the nature of the restrictions be disclosed. The University adopted this standard for fiscal year 2020 on a retrospective basis.

2. University of Pennsylvania Health System - Summarized Financial and Related Information

The Trustees formed Penn Medicine, the governance structure which oversees the activities of UPHS and the University of Pennsylvania Perelman School of Medicine (PSOM) in order to operate, oversee and coordinate its academic, research and clinical missions.

UPHS is comprised of the following operating entities: Clinical Practices of the University of Pennsylvania; Clinical Care Associates; Hospital of the University of Pennsylvania; Penn Presbyterian Medical Center; Pennsylvania Hospital of the University of Pennsylvania Health System; Chester County Hospital and Health System; Lancaster General Health (LGH); Wissahickon Hospice of the University of Pennsylvania Health System; Princeton HealthCare System (PHCS);

Consolidated Notes to Financial Statements

Franklin Casualty Insurance Company, a wholly owned Risk Retention Group; and, Quaker Insurance Company Ltd., a wholly owned offshore captive insurance company, (collectively referred to as RRG/Captive).

Throughout the year, certain transactions (primarily billings for allocations of common costs, physicians' salaries and benefits, certain purchased services and support for PSOM) are conducted between UPHS and the University. Nonoperating, net, as shown below, includes transfers from UPHS to the University of \$207,085,000 and \$234,722,000 in 2020 and 2019, respectively, to further the research and educational activities of PSOM and \$6,581,000 and \$5,671,000 in 2020 and 2019, respectively, for other activities. In addition, UPHS recognized operating expenses of \$19,618,000 and \$19,770,000 in 2020 and 2019, respectively, to support academic operating activities in the clinical departments of PSOM.

The effect of all these transactions is included in the following summarized financial information of UPHS as of and for the years ended June 30, 2020 and 2019 (in thousands):

| | 2020 | 2019 |
|---|---------------|---------------|
| Net patient service revenue | \$ 6,813,226 | \$ 6,940,977 |
| Other revenue | 994,662 | 653,071 |
| Total expenses | (7,565,166) | (7,156,362) |
| Excess of revenue over expenses from operations | 242,722 | 437,686 |
| Nonoperating, net | (393,237) | (310,922) |
| (Decrease) increase in net assets | \$ (150,515) | \$ 126,764 |
| Total current assets | \$ 2,554,537 | \$ 1,876,193 |
| Assets whose use is limited: | | |
| Held by trustees | 139,028 | 163,598 |
| RRG/Captive | 243,622 | 219,879 |
| Donor restricted and other | 657,776 | 678,137 |
| Designated | 2,833,871 | 2,731,038 |
| Property and equipment, net | 5,369,409 | 4,760,563 |
| Investments and other assets | 1,361,266 | 1,152,231 |
| Total assets | \$ 13,159,509 | \$ 11,581,639 |
| Total current liabilities | \$ 1,973,427 | \$ 1,243,888 |
| Long-term debt, net of current portion | 2,692,254 | 2,283,002 |
| Other liabilities | 2,722,567 | 2,132,973 |
| Total liabilities | \$ 7,388,248 | \$ 5,659,863 |
| Net assets | | |
| Without donor restrictions | \$ 5,098,229 | \$ 5,234,000 |
| With donor restrictions | 673,032 | 687,776 |
| Total net assets | \$ 5,771,261 | \$ 5,921,776 |
| Total liabilities and net assets | \$ 13,159,509 | \$ 11,581,639 |

Net Patient Service Revenue

Net Patient Service Revenue (NPSR) for the years ended June 30, 2020 and 2019 is derived from the following payers:

| | 2020 | 2019 |
|---------------------------------------|------|------|
| Medicare (including Managed Medicare) | 32% | 34% |
| Medicaid (including Managed Medicaid) | 12% | 10% |
| Managed Care | 36% | 35% |
| Independence Blue Cross (IBC) | 15% | 16% |
| Commercial | 4% | 4% |
| Self Pay | 1% | 1% |
| | 100% | 100% |

UPHS has agreements with the following third-party payers that provide for payments at amounts that differ from its established rates:

Inpatient acute care services and outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors. Inpatient psychiatric services and medical education costs related to Medicare beneficiaries are paid based on a cost reimbursement methodology. UPHS is reimbursed for cost reimbursable items at a tentative rate with final settlement determined after submission of annual cost reports by each hospital and audits thereof by the Medicare fiscal intermediary.

Inpatient and outpatient services rendered to Medicaid program beneficiaries are paid at prospectively determined rates. Additional amounts are allocated to each hospital for training residents and serving a disproportionate indigent population.

Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.

During 2017, UPHS and IBC reached agreement on terms of a five-year agreement. Payments made for inpatient services provided to IBC traditional and managed care subscribers are effected on a per case rate basis for most services. Payment for outpatient services is principally based upon negotiated fee schedules. Hospital and physician rates also provide for annual inflationary increases. In addition, incentives are paid for high performance with regard to clinical outcomes and patient quality. The agreement continues unless terminated by the parties.

During 2015, UPHS and Aetna reached agreement on terms of a five-year agreement. A one-year bridge agreement is effective July 1, 2020. The terms of the agreement provide payments for inpatient hospital services on a per case rate basis. Payments for outpatient services continue to be predominantly based upon negotiated fee schedules.

UPHS also has reimbursement agreements with other commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis for reimbursement under these agreements includes prospectively determined rates per discharge, discounts from established charges and prospectively determined per diem rates.

Charity Care

UPHS provides services to patients who meet certain criteria under its charity care policy without charge or at amounts less than UPHS' established rates. Because UPHS does not pursue collections, such amounts have been excluded from NPSR. UPHS estimates the costs of providing charity care services based on data derived from a combination of UPHS' cost accounting system and the ratio of costs to charges. Of the Total expenses reported above by UPHS, an estimated \$29,793,000 and \$24,968,000 were incurred as a result of providing services to charity patients for the years ended June 30, 2020 and 2019, respectively.

Medical Professional Liability Claims

The University is insured for medical professional liability claims through the combination of the Medical Care Availability and Reduction of Error Fund (Mcare), various commercial insurance companies and risk retention programs.

Mcare levies health care provider surcharges, as a percentage of the Pennsylvania Joint Underwriters Association rates for basic coverage, to pay claims and pay administrative expenses of Mcare participants. These surcharges are recognized as expenses in the period incurred. Mcare operates on a pay-as-you-go basis and no provision has been made for any future Mcare assessments in the accompanying financial statements, as the University's portion of the unfunded Mcare liability cannot be estimated.

Anticipated insurance recoveries and estimated liabilities for medical malpractice claims or similar contingent liabilities are presented separately on the Consolidated Statement of Financial Position in Accounts receivable, net of allowances and Accrued expenses and other liabilities, respectively. The University accrues for estimated risks arising from both asserted and unasserted medical professional liability claims. The estimate of the gross liability and corresponding receivable for unasserted claims arising from unreported incidents is based on analysis of historical claims data by an independent actuary, which is recorded utilizing a 2.25% to 3.50% discount rate as of June 30, 2020 and 2019. The gross liability recorded under this program is \$750,633,000 and \$732,389,000 at June 30, 2020 and 2019, respectively, with a corresponding receivable of \$119,255,000 and \$103,777,000 at June 30, 2020 and 2019, respectively.

3. Accounts Receivable

Accounts receivable are reported at their net realizable value. The major components of receivables, net of allowances for doubtful accounts of \$22,771,000 and \$22,086,000 at June 30, 2020 and 2019, respectively, are as follows (in thousands):

| | 2020 | | 2019 | |
|---------------------------|------|---------|------|---------|
| Sponsored research | \$ | 159,528 | \$ | 130,161 |
| Malpractice | | 119,255 | | 103,777 |
| Student | | 26,450 | | 18,614 |
| Trade | | 63,233 | | 60,949 |
| Investment income | | 4,343 | | 8,096 |
| Other | | 134,230 | | 76,461 |
| Total Accounts receivable | \$ | 507,039 | \$ | 398,058 |

4. Loans Receivable

Loans receivable, and related allowances for doubtful accounts, consist of the following at June 30, 2020 and 2019 (in thousands):

| 2020 | | | | |
|-----------------------------|------------|--------|-----------|-----------|
| | Receivable | | Allowance | |
| | | | Net | |
| Student Loans: | | | | |
| Federally-sponsored | \$ | 42,410 | \$ | 42,410 |
| Other | | 13,748 | \$ | 2,994 |
| Total Student loans | \$ | 56,158 | \$ | 2,994 |
| Other | | 10,658 | | 424 |
| Total Loans receivable, net | \$ | 66,816 | \$ | 3,418 |
| | | | | \$ 63,398 |

| 2019 | | | | |
|-----------------------------|------------|--------|-----------|-----------|
| | Receivable | | Allowance | |
| | | | Net | |
| Student Loans: | | | | |
| Federally-sponsored | \$ | 50,509 | \$ | 50,509 |
| Other | | 14,406 | \$ | 3,275 |
| Total Student loans | \$ | 64,915 | \$ | 3,275 |
| Other | | 10,964 | | 242 |
| Total Loans receivable, net | \$ | 75,879 | \$ | 3,517 |
| | | | | \$ 72,362 |

Loans receivable primarily consists of student loans. Student loans include federally-sponsored student loans and donor-restricted student loans with mandated interest rates and repayment terms. The federally-sponsored student loans represent amounts due from current and former students under various Federal Government funded loan programs offered to graduate and undergraduate students. Loans disbursed under these programs are able to be assigned to the Federal Government upon default by the borrower; therefore, no related allowance is considered necessary. Funding received under these programs is ultimately refundable to the Federal Government in the event the University no longer participates and accordingly is reported as a liability in Federal student loan advances in the Consolidated Statements of Financial Position. Determination of the fair value of student loans receivable is not practicable.

Loans receivable are reported at their net realizable value. The University regularly assesses the adequacy of the allowances for credit losses of its loans by performing ongoing evaluations, including such factors as aging, differing economic risks associated with each loan category, financial condition of specific borrowers, economic environment in which the borrowers operate, level of delinquent loans, value of collateral and existence of guarantees or indemnifications.

5. Contributions Receivable

A summary of contributions receivable at June 30, 2020 and 2019, is as follows (in thousands):

| | 2020 | 2019 |
|---|------------|------------|
| Unconditional promises expected to be collected in: | | |
| Less than one year | \$ 169,979 | \$ 171,791 |
| One year to five years | 249,791 | 280,978 |
| Over five years | 120,726 | 117,343 |
| | 540,496 | 570,112 |
| Less: Discount | (27,699) | (45,638) |
| Less: Allowances for doubtful amounts | (34,647) | (36,024) |
| Total Contributions receivable, net | \$ 478,150 | \$ 488,450 |

At June 30, 2020 and 2019, the University has outstanding unrecorded conditional promises to give, including non-legally binding bequests, of \$467,797,000 and \$474,184,000, respectively. When conditional promises to give become unconditional or non-legally binding bequests cash payments are received, they are recorded and are generally restricted for operations, endowment and capital projects as stipulated by the donors.

6. Investments, at Fair Value

A summary of investments, including the AIF, as of June 30, 2020 and 2019, categorized in accordance with the fair value hierarchy, is as follows (in thousands):

| Assets | Level 1 | Level 2 | Level 3 | Investments at NAV | 2020 |
|---------------------------|--------------|------------|------------|--------------------|---------------|
| Short-term | \$ 594,126 | | | | \$ 594,126 |
| Equity: | | | | | |
| US equities | 719,227 | | | \$ 1,299,712 | 2,018,939 |
| International equities | 141,939 | | | 1,111,548 | 1,253,487 |
| Emerging market equities | 175,705 | | | 1,087,617 | 1,263,322 |
| Total Equity | 1,036,871 | | | 3,498,877 | 4,535,748 |
| Debt: | | | | | |
| US treasuries | 1,642,721 | \$ 19,999 | | | 1,662,720 |
| Corporate bonds | 1,449 | 114,512 | | | 115,961 |
| High yield | | | | 119 | 119 |
| Total Debt | 1,644,170 | 134,511 | | 119 | 1,778,800 |
| Split-interest agreements | 87,085 | | \$ 325,701 | | 412,786 |
| Absolute return | | | | 3,893,852 | 3,893,852 |
| Real estate | | 59 | | 978,372 | 978,431 |
| Private equity | | | 14,473 | 4,110,984 | 4,125,457 |
| Natural resources | 86,075 | | | 445,171 | 531,246 |
| Derivative instruments | | 17,132 | | | 17,132 |
| Other | | | 2,538 | | 2,538 |
| Total assets | \$ 3,448,327 | \$ 151,702 | \$ 342,712 | \$ 12,927,375 | \$ 16,870,116 |

| Assets | Level 1 | Level 2 | Level 3 | Investments at NAV | 2019 |
|---------------------------|--------------|------------|------------|--------------------|---------------|
| Short-term | \$ 1,188,571 | | | | \$ 1,188,571 |
| Equity: | | | | | |
| US equities | 721,261 | | | \$ 1,077,918 | 1,799,179 |
| International equities | 190,694 | | | 1,055,871 | 1,246,565 |
| Emerging market equities | 153,435 | | | 1,091,866 | 1,245,301 |
| Total Equity | 1,065,390 | | | 3,225,655 | 4,291,045 |
| Debt: | | | | | |
| US treasuries | 1,716,743 | \$ 41,860 | | | 1,758,603 |
| Corporate bonds | 1,548 | 100,706 | | 26,849 | 129,103 |
| High yield | | | | 98 | 98 |
| Total Debt | 1,718,291 | 142,566 | | 26,947 | 1,887,804 |
| Split-interest agreements | 86,492 | | \$ 322,631 | | 409,123 |
| Absolute return | | | | 3,259,286 | 3,259,286 |
| Real estate | | 59 | | 804,620 | 804,679 |
| Private equity | | | 14,426 | 3,832,884 | 3,847,310 |
| Natural resources | 157,440 | | | 650,414 | 807,854 |
| Derivative instruments | | 1,167 | | | 1,167 |
| Other | | | 2,547 | | 2,547 |
| Total assets | \$ 4,216,184 | \$ 143,792 | \$ 339,604 | \$ 11,799,806 | \$ 16,499,386 |

Included in Short-term investments is \$20,947,000 and \$43,287,000 of amounts held by trustees under indenture and escrow agreements at June 30, 2020 and 2019, respectively.

Consolidated Notes to Financial Statements

At June 30, 2020 and 2019, Short-term investments include \$40,915,000 and \$85,301,000, respectively, of outstanding receivables from trading activities. At June 30, 2020 and 2019, Short-term investments also include \$64,542,000 and \$49,929,000, respectively, of outstanding payables from trading activities.

As of June 30, 2020 and 2019 there were no transfers between Level 1 and 2.

Liabilities related to equity short positions of \$329,955,000 and \$362,826,000 at June 30, 2020 and 2019, respectively, are reported in Accrued expenses and other liabilities on the Consolidated Statements of Financial Position. These liabilities are valued using observable market data and are categorized as Level 1 based on quoted market prices in active markets.

The University has made investments in various long-lived partnerships and, in other cases, has entered into contractual agreements that may limit its ability to initiate redemptions due to notice periods, lock-ups and gates. The University has also made commitments to various limited partnerships. The University expects these funds to be called over the next 5 years. The total amount of unfunded commitments is \$3,316,965,000 which represents 23.3% of the AIF value as of June 30, 2020.

Consolidated Notes to Financial Statements

Details on the fair value, remaining estimated life, outstanding commitments, current redemption terms and restrictions by strategy and type of investment are provided below (in thousands):

| Strategy | Fair Value | | Outstanding Commitments | Redemption Terms | Redemption Restrictions |
|-------------------------|---------------|---------------|----------------------------|--|--|
| | June 30, 2020 | June 30, 2019 | | | |
| Short-term | \$ 594,126 | \$ 1,188,571 | | Daily | None |
| Equity | | | | | |
| Managed accounts | 761,773 | 764,350 | | Daily and semi-annually with varying notice periods | None |
| Mutual funds | 275,098 | 257,144 | | Daily | None |
| Private funds (1) | 3,498,877 | 3,269,551 | \$ 47,550 | Weekly to annually with varying notice periods | Lock-up provisions ranging from 0 to 5 years and side pocket investments (2) |
| Total Equity | 4,535,748 | 4,291,045 | 47,550 | | |
| Debt | | | | | |
| Managed accounts | 1,778,681 | 1,860,857 | | Daily | None |
| Private funds (1) | 119 | 26,947 | | Daily | None; side pocket investments (2) |
| Total Debt | 1,778,800 | 1,887,804 | | | |
| Absolute return | 3,893,852 | 3,259,286 | 230,186 | Range from monthly to annually and close-ended funds not available for redemption | Lock-up provisions ranging from 0 to 5 years with earlier redemptions subject to redemption fee, close-ended funds not available for redemption, and side pocket investments (2) |
| Real estate | 978,431 | 804,679 | 923,667 | Close-ended funds not available for redemption | Close-ended funds not available for redemption |
| Private equity | 4,125,457 | 3,847,310 | 1,899,101 | Close-ended funds not available for redemption | Close-ended funds not available for redemption |
| Natural resources | | | | | |
| Managed accounts | 86,075 | 149,433 | | Daily | None |
| Private funds (1) | 445,171 | 658,421 | 216,461 | Close-ended funds not available for redemption | Close-ended funds not available for redemption |
| Total Natural Resources | 531,246 | 807,854 | 216,461 | | |
| Totals | \$ 16,437,660 | \$ 16,086,549 | \$ 3,316,965 | | |

(1) Private funds consist of close-ended and open-ended funds generally in the form of limited partnerships. Close-ended funds have varying remaining fund terms between 1 to 15 years.

(2) Side pocket investments represent investments designated by a manager that are not available for liquidity in an otherwise liquid fund vehicle.

Included in Level 1 split-interest agreement investments above are readily marketable assets invested by the University separately from the AIF where the University serves as trustee with an aggregate fair value of \$87,085,000 and \$86,492,000 at June 30, 2020 and 2019, respectively. These amounts include assets related to the University Academic Component charitable gift annuities totaling \$43,979,000 and \$42,158,000 at June 30, 2020 and 2019, respectively. Included in these split-interest agreement investments are amounts held to meet legally mandated annuity reserves of \$29,006,000 and \$27,323,000 as of June 30, 2020 and 2019, respectively, as required by the laws of the following states where certain individual donors reside: California, Maryland, New Jersey and New York. Level 3 split-interest agreement investments are managed and invested outside of the University by external trustees.

Invested in the AIF with an aggregate fair value of \$168,792,000 and \$171,392,000 at June 30, 2020 and 2019, respectively, is a perpetual trust managed by an external trustee who has delegated investment decisions to the University. The University invests the assets of this trust in accordance with its endowment policy.

Consolidated Notes to Financial Statements

A summary of Level 3 assets included in split-interest agreement investments, where the University is not trustee, measured at fair value, as of June 30, 2020 and 2019 is as follows (in thousands):

| | 2020 | 2019 |
|-----------------------------|------------|------------|
| Charitable remainder trusts | \$ 19,487 | \$ 18,511 |
| Charitable lead trusts | 5,763 | 4,568 |
| Perpetual trusts | 300,451 | 299,552 |
| Total | \$ 325,701 | \$ 322,631 |

Changes to the reported amounts of split-interest agreement investments measured at fair value using unobservable (Level 3) inputs as of June 30, 2020 and 2019 are as follows (in thousands):

| | Charitable Remainder Trusts | Charitable Lead Trusts | Perpetual Trusts | Total |
|-------------------------------|--------------------------------|------------------------------|---------------------|------------|
| June 30, 2019 | \$ 18,511 | \$ 4,568 | \$ 299,552 | \$ 322,631 |
| Net realized gains | | | 2,974 | 2,974 |
| Net unrealized gains/(losses) | 976 | 1,225 | (2,610) | (409) |
| Acquisitions | | | 535 | 535 |
| Liquidations | | (30) | | (30) |
| June 30, 2020 | \$ 19,487 | \$ 5,763 | \$ 300,451 | \$ 325,701 |

| | Charitable Remainder Trusts | Charitable Lead Trusts | Perpetual Trusts | Total |
|-------------------------------|--------------------------------|------------------------------|---------------------|------------|
| June 30, 2018 | \$ 17,239 | \$ 5,621 | \$ 298,116 | \$ 320,976 |
| Net realized gains | | | 6,994 | 6,994 |
| Net unrealized gains/(losses) | 724 | (1,023) | (4,055) | (4,354) |
| Acquisitions | 1,191 | | | 1,191 |
| Liquidations | (643) | (30) | (1,503) | (2,176) |
| June 30, 2019 | \$ 18,511 | \$ 4,568 | \$ 299,552 | \$ 322,631 |

The following tables set forth the fair value, related gains (losses) and notional amounts of the University's derivative instruments by contract type as of June 30, 2020 and 2019 (in thousands):

| | 2020 | | | |
|----------------------------|-----------------|----------------------------|---------------------------------|---------------------|
| | Notional Amount | Gross Derivative Assets | Gross Derivative Liabilities | Derivative Gains |
| Foreign currency contracts | \$ 112,672 | \$ 301 | \$ 916 | \$ (2,442) |
| Futures contracts | (542,830) | 16,403 | | (17,423) |
| Options contracts | (125,284) | 428 | 1,306 | (7,606) |
| Total | \$ (555,442) | \$ 17,132 | \$ 2,222 | \$ (27,471) |

Consolidated Notes to Financial Statements

2019

| | Notional Amount | Gross Derivative Assets | Gross Derivative Liabilities | Derivative Losses |
|----------------------------|-----------------|-------------------------|------------------------------|-------------------|
| Foreign currency contracts | \$ 121,124 | \$ 1,167 | \$ 33 | \$ 369 |
| Futures contracts | (398,548) | | | 3,210 |
| Options contracts | (122,014) | | 627 | |
| Total | \$ (399,438) | \$ 1,167 | \$ 660 | \$ 3,579 |

The notional amount is representative of the volume and activity of the respective derivative type during the years ended June 30, 2020 and 2019.

Gross derivatives assets and liabilities are shown on the Consolidated Statements of Financial Position in Investments, at fair value and Accrued expenses and other liabilities, respectively. Derivative gains (losses) are shown in Return on investments, net on the Consolidated Statements of Activities, in the appropriate net asset classification.

A summary of the University's total investment return, net of external and direct internal investment expenses, for the years ended June 30, 2020 and 2019 is presented below (in thousands):

| | 2020 | 2019 |
|-----------------------------------|------------|------------|
| AIF investment income | \$ 59,105 | \$ 90,494 |
| AIF realized and unrealized gains | 457,907 | 793,459 |
| Return on AIF | 517,012 | 883,953 |
| Other investment gains | 37,940 | 69,588 |
| Total Return on investments, net | \$ 554,952 | \$ 953,541 |

7. Endowment

The composition and changes to the amount of the University's endowment at June 30, 2020 are as follows (in thousands):

| | Without Donor Restrictions | With Donor Restrictions | Total |
|----------------------------------|----------------------------|-------------------------|---------------|
| Donor-restricted endowment funds | | \$ 7,513,627 | \$ 7,513,627 |
| Quasi-endowment funds | \$ 7,363,736 | | 7,363,736 |
| June 30, 2020 | \$ 7,363,736 | \$ 7,513,627 | \$ 14,877,363 |

| | Without Donor Restrictions | With Donor Restrictions | Total |
|--|----------------------------|-------------------------|---------------|
| Net assets, June 30, 2019 | \$ 7,252,228 | \$ 7,397,533 | \$ 14,649,761 |
| Investment return | 123,658 | 216,502 | 340,160 |
| New gifts | 11,219 | 236,657 | 247,876 |
| Allocation of endowment assets for expenditure | (654,691) | | (654,691) |
| Other investment allocation | (6,918) | | (6,918) |
| Transfers to create board designated funds | 302,623 | | 302,623 |
| Donor imposed Income Reinvestments | | 955 | 955 |
| Other transfers | 21,940 | (24,343) | (2,403) |
| Released from restriction | 313,677 | (313,677) | |
| Net assets, June 30, 2020 | \$ 7,363,736 | \$ 7,513,627 | \$ 14,877,363 |

Consolidated Notes to Financial Statements

The composition and changes to the amount of the University's endowment as of June 30, 2019 are as follows (in thousands):

| | Without Donor Restrictions | With Donor Restrictions | Total |
|----------------------------------|-------------------------------|-------------------------------|---------------|
| Donor-restricted endowment funds | | \$ 7,397,533 | \$ 7,397,533 |
| Quasi-endowment funds | \$ 7,252,228 | | 7,252,228 |
| June 30, 2019 | \$ 7,252,228 | \$ 7,397,533 | \$ 14,649,761 |

| | Without Donor Restrictions | With Donor Restrictions | Total |
|--|-------------------------------|-------------------------------|---------------|
| Net assets, June 30, 2018 | \$ 6,828,370 | \$ 6,949,071 | \$ 13,777,441 |
| Investment return | 414,032 | 400,565 | 814,597 |
| New gifts | 6,999 | 357,012 | 364,011 |
| Allocation of endowment assets for expenditure | (577,039) | | (577,039) |
| Other investment allocation | (3,793) | | (3,793) |
| Transfers to create board designated funds | 288,291 | | 288,291 |
| Other transfers | 3,634 | (17,381) | (13,747) |
| Released from restriction | 291,734 | (291,734) | |
| Net assets, June 30, 2019 | \$ 7,252,228 | \$ 7,397,533 | \$ 14,649,761 |

At June 30, 2020 and 2019, the aggregate amount of funds reported in Net assets with donor restrictions for which the fair value was below historic value was \$1,265,000 and \$0, respectively.

8. Property, Plant and Equipment, net

The components of PPE at June 30, 2020 and 2019 are as follows (in thousands):

| | Estimated Useful Life in years | 2020 | 2019 |
|------------------------------------|-----------------------------------|--------------|--------------|
| Land and land improvements | N/A to 20 | \$ 423,467 | \$ 438,885 |
| Buildings and fixed equipment | 5 to 50 | 10,475,473 | 10,032,085 |
| Moveable equipment and other | 4 to 20 | 2,136,837 | 2,013,160 |
| Construction-in-progress | | 2,046,652 | 1,354,708 |
| | | 15,082,429 | 13,838,838 |
| Less: Accumulated depreciation | | (6,304,344) | (5,809,846) |
| Property, plant and equipment, net | | \$ 8,778,085 | \$ 8,028,992 |

The University recorded \$533,289,000 and \$539,372,000 of depreciation expense for the years ended June 30, 2020 and 2019, respectively.

The University capitalized \$55,940,000 and \$35,748,000 of interest costs for the years ended June 30, 2020 and 2019, respectively.

The University has conditional asset retirement obligations of \$15,278,000 and \$16,320,000 as of June 30, 2020 and 2019, respectively, which primarily relate to asbestos contained in buildings and underground steam distribution piping and are included within Accrued expenses and other liabilities in the Consolidated Statements of Financial Position.

9. Split-Interest Agreements

Changes in the value of assets, liabilities and net assets pursuant to split-interest agreements as of June 30, 2020 and 2019 are as follows (in thousands):

| 2020 | | Assets | | Liabilities | | Net Assets |
|-----------------------------------|----|---------------|----|--------------------|----|-------------------|
| June 30, 2019 | \$ | 409,123 | \$ | (50,311) | \$ | 358,812 |
| New contributions | | 7,418 | | (3,951) | | 3,467 |
| Investment income | | 2,038 | | (1,673) | | 365 |
| Realized and unrealized gain, net | | 2,515 | | | | 2,515 |
| Payments and settlements | | (8,308) | | 7,517 | | (791) |
| Actuarial adjustment | | | | (2,418) | | (2,418) |
| Net change | | 3,663 | | (525) | | 3,138 |
| June 30, 2020 | \$ | 412,786 | \$ | (50,836) | \$ | 361,950 |
| 2019 | | Assets | | Liabilities | | Net Assets |
| June 30, 2018 | \$ | 398,793 | \$ | (46,965) | \$ | 351,828 |
| New contributions | | 8,552 | | (8,898) | | (346) |
| Investment income | | 1,882 | | (1,545) | | 337 |
| Realized and unrealized gain, net | | 7,787 | | | | 7,787 |
| Payments and settlements | | (7,891) | | 8,593 | | 702 |
| Actuarial adjustment | | | | (1,496) | | (1,496) |
| Net change | | 10,330 | | (3,346) | | 6,984 |
| June 30, 2019 | \$ | 409,123 | \$ | (50,311) | \$ | 358,812 |

10. Contingencies, Guarantees and Commitments

The University offers various loan programs for students and families to pay tuition, fees and other costs. Certain loans issued by private lending institutions are guaranteed by the University totaling \$20,644,000 and \$27,979,000 at June 30, 2020 and 2019, respectively. Upon default by the borrower, the University is required to pay all or a portion of the outstanding loan balance. The University recognizes a liability for the greater of the fair value of the guarantee or defaults in the portfolio of guaranteed loans. The recognized liability is \$3,005,000 and \$3,182,000 at June 30, 2020 and 2019, respectively and reflects the fair value of the guarantee on these outstanding loan balances.

Various lawsuits, claims and other contingent liabilities arise in the ordinary course of the University's education and health care activities. Based upon information currently available, management believes that any liability resulting therefrom will not materially affect the financial position or operations of the University.

The University is currently involved in various projects that have resulted in capital and property acquisition commitments from the University. As of June 30, 2020, approximately \$486,351,000 has been committed by the University.

11. Pension and Other Postretirement Benefit Costs

Retirement benefits are principally provided to employees through contributory defined contribution plans. The Academic Component's policy with respect to its contribution is to provide up to 9% of eligible employees' salaries, while the UPHS contribution can be up to 6.5%. The University's contributions to these plans amounted to \$231,054,000 and \$212,316,000 as of June 30, 2020 and 2019, respectively.

The University also has non-contributory defined benefit pension plans. Benefits under the plans generally are based on the employee's years of service and compensation during the years preceding retirement. Contributions to the plans are made in amounts necessary to at least satisfy the minimum required contributions as specified in the Internal Revenue Service Code and related regulations. The Academic Component's plan was frozen to new full-time entrants effective July 1, 2000 and part-time entrants effective July 1, 2018. UPHS' primary plan was frozen to new entrants effective July 1, 2010; the benefit accruals for all participants of the LGH and PHCS plans were frozen effective June 30, 2013 and December 31, 2011, respectively. In June 2020, UPHS paid \$78,879,000 from plan assets to an insurance company to buy out the total pension benefit for a portion of its retired participants.

Additionally, the University provides certain healthcare and life insurance benefits (OPEB) for retired employees. Only a limited number of employees may become eligible for such benefits if they reach retirement age while working for the University. These and similar benefits for active and certain retired employees are provided through insurance contracts.

The University uses a measurement date of June 30 for its defined benefit pension and OPEB plans.

Change in Plan Assets/ Obligation and Funded Status

The funded status of the plans is measured as the difference between the plan assets at fair value and the projected benefit obligation (PBO) for Pension Benefits or accumulated postretirement benefit obligation (APBO) for Other Postretirement Benefits. The resulting net liability is recorded in Accrued retirement benefits on the Statements of Financial Position. The following shows changes in the benefit obligation, plan assets and funded status (in thousands):

| 2020 | Pension Benefits | Other Postretirement Benefits | Total |
|--|---------------------|-------------------------------------|--------------|
| Change in Plan Assets | | | |
| Fair value of plan assets, beginning of year | \$ 2,696,740 | \$ 522,365 | \$ 3,219,105 |
| University contributions | 130,008 | 42,698 | 172,706 |
| Plan participants' contributions | 151 | 8,729 | 8,880 |
| Actual return on plan assets | 150,317 | 17,778 | 168,095 |
| Benefits paid | (184,881) | (36,619) | (221,500) |
| Fair value of plan assets, end of year | \$ 2,792,335 | \$ 554,951 | \$ 3,347,286 |
| Change in Benefit Obligation | | | |
| Benefit obligation, beginning of year (PBO/APBO) | \$ 3,750,476 | \$ 1,014,328 | \$ 4,764,804 |
| Service cost | 77,085 | 35,476 | 112,561 |
| Interest cost | 136,674 | 38,148 | 174,822 |
| Plan participants' contributions | 151 | 8,729 | 8,880 |
| Net actuarial (gain)/loss | 342,211 | 30,238 | 372,449 |
| Benefits paid | (184,881) | (36,619) | (221,500) |
| Benefit obligation, end of year (PBO/APBO) | \$ 4,121,716 | \$ 1,090,300 | \$ 5,212,016 |
| Funded status, end of year | \$ 1,329,381 | \$ 535,349 | \$ 1,864,730 |
| Other retirement programs | | | 103,521 |
| Accrued retirement benefits | | | \$ 1,968,251 |

Consolidated Notes to Financial Statements

| 2019 | Pension Benefits | Other Postretirement Benefits | Total |
|--|-----------------------------|--|--------------|
| Change in Plan Assets | | | |
| Fair value of plan assets, beginning of year | \$ 2,590,798 | \$ 505,340 | \$ 3,096,138 |
| University contributions | 87,634 | 32,244 | 119,878 |
| Plan participants' contributions | 159 | 6,419 | 6,578 |
| Actual return on plan assets | 120,702 | 13,198 | 133,900 |
| Benefits paid | (102,553) | (34,836) | (137,389) |
| Fair value of plan assets, end of year | \$ 2,696,740 | \$ 522,365 | \$ 3,219,105 |
| Change in Benefit Obligation | | | |
| Benefit obligation, beginning of year (PBO/APBO) | \$ 3,319,649 | \$ 916,367 | \$ 4,236,016 |
| Service cost | 68,923 | 30,269 | 99,192 |
| Interest cost | 139,344 | 38,741 | 178,085 |
| Plan participants' contributions | 159 | 6,419 | 6,578 |
| Net actuarial (gain)/loss | 324,954 | 57,368 | 382,322 |
| Benefits paid | (102,553) | (34,836) | (137,389) |
| Benefit obligation, end of year (PBO/APBO) | \$ 3,750,476 | \$ 1,014,328 | \$ 4,764,804 |
| Funded status, end of year | \$ 1,053,736 | \$ 491,963 | \$ 1,545,699 |
| Other retirement programs | | | 105,986 |
| Accrued retirement benefits | | | \$ 1,651,685 |

The Accumulated Benefit Obligation for the Pension Benefits was \$3,766,340,000 and \$3,354,141,000 at June 30, 2020 and 2019, respectively.

Net Periodic Benefit Cost

The components of net periodic benefit cost for pension benefits and other postretirement benefits are detailed below (in thousands). In the Consolidated Statements of Activities, service cost is reported as Compensation and benefits while the remaining components of net periodic benefit cost are reported as Pension, OPEB and other, net.

| 2020 | Pension Benefits | Other Postretirement Benefits | Total |
|--------------------------------|-----------------------------|--|--------------|
| Net Periodic Cost | | | |
| Service cost | \$ 77,085 | \$ 35,476 | \$ 112,561 |
| Interest cost | 136,674 | 38,148 | 174,822 |
| Expected return on plan assets | (184,845) | (39,251) | (224,096) |
| Amortization of: | | | |
| Net prior service cost | | (387) | (387) |
| Net losses | 53,500 | 6,992 | 60,492 |
| Net periodic benefit cost | \$ 82,414 | \$ 40,978 | \$ 123,392 |

Consolidated Notes to Financial Statements

| 2019 | Pension Benefits | Other Postretirement Benefits | Total |
|--------------------------------|---------------------|-------------------------------------|------------|
| Net Periodic Cost | | | |
| Service cost | \$ 68,923 | \$ 30,269 | \$ 99,192 |
| Interest cost | 139,344 | 38,741 | 178,085 |
| Expected return on plan assets | (169,595) | (37,969) | (207,564) |
| Amortization of: | | | |
| Net prior service cost | | (386) | (386) |
| Net losses | 30,968 | 2,447 | 33,415 |
| Net periodic benefit cost | \$ 69,640 | \$ 33,102 | \$ 102,742 |

Net Assets Without Donor Restrictions

The University recorded the following year-end valuation adjustments to its Pension and Other Postretirement Benefit Plans in Pension, OPEB and Other, net in the Consolidated Statements of Activities (in thousands):

| 2020 | Pension Benefits | Other Postretirement Benefits | Total |
|---|---------------------|-------------------------------------|--------------|
| Net Assets Without Donor Restrictions | | | |
| Net actuarial loss | \$ 1,251,922 | \$ 239,885 | \$ 1,491,807 |
| Net prior service cost/(credit) | | (2,372) | (2,372) |
| Total | \$ 1,251,922 | \$ 237,513 | \$ 1,489,435 |
| Adjustment to net assets without donor restrictions (gain)/loss | \$ 323,237 | \$ 45,107 | \$ 368,344 |

| 2019 | Pension Benefits | Other Postretirement Benefits | Total |
|---|---------------------|-------------------------------------|--------------|
| Net Assets Without Donor Restrictions | | | |
| Net actuarial loss | \$ 928,685 | \$ 195,165 | \$ 1,123,850 |
| Net prior service cost/(credit) | | (2,759) | (2,759) |
| Total | \$ 928,685 | \$ 192,406 | \$ 1,121,091 |
| Adjustment to net assets without donor restrictions (gain)/loss | \$ 342,879 | \$ 80,077 | \$ 422,956 |

The estimated amount that will be amortized from Net assets without donor restrictions into net periodic benefit cost in 2021 is as follows (in thousands):

| | Pension Benefits | Other Postretirement Benefits |
|--------------------------------------|---------------------|-------------------------------------|
| Amortization of prior service credit | | \$ (387) |
| Amortization of net losses | \$ 77,225 | 9,765 |

Actuarial Assumptions

The expected long-term rate of return on plan assets is management's best estimate of the average investment return expected to be received on the assets invested in the plan over the benefit period. The expected long-term rate of return on plan assets has been established by considering historical and future expected returns of the asset classes invested in by the pension trust, and the allocation strategy currently in place among those classes.

Consolidated Notes to Financial Statements

| | Pension Benefits | | Other Postretirement Benefits | |
|---|---------------------|-------|----------------------------------|-------|
| Weighted-Average Assumptions Used to Determine Benefit Obligations at Year End | | | | |
| | 2020 | 2019 | 2020 | 2019 |
| Discount rate | 3.05% | 3.72% | 3.28% | 3.81% |
| Salary increase | 3.22% | 3.92% | N/A | N/A |
| Weighted-Average Assumptions Used to Determine Net Periodic Benefit Cost | | | | |
| | 25 | | | |
| Discount rate | 3.72% | 4.26% | 3.81% | 4.29% |
| Expected long-term return on plan assets | 7.26% | 7.30% | 7.50% | 7.50% |
| Salary increase | 4.03% | 3.80% | N/A | N/A |
| Assumed Health Care Cost Trend Rates | | | | |
| Initial trend rate | N/A | N/A | 6.24% | 6.28% |
| Ultimate trend rate | N/A | N/A | 4.72% | 4.71% |
| Fiscal year end that ultimate trend rate is reached | N/A | N/A | 2037 | 2037 |

Assumed health care cost trend rates have a significant effect on the amounts reported for the Other postretirement benefits. A one-percentage-point change in assumed health care trend rates would have the following effects on Other postretirement benefits (in thousands):

| | 1-Percentage Point Increase | 1-Percentage Point Decrease |
|--|-----------------------------|-----------------------------|
| 2020 | | |
| Effect on total of service and interest cost | \$ 20,125 | \$ (14,723) |
| Effect on APBO | 224,798 | (172,029) |

Expected Contributions

The University expects to contribute \$133,894,000 and \$31,171,000 for pension benefits and other postretirement benefits, respectively, during the fiscal year ending June 30, 2021.

Expected Benefits Payments (in thousands):

| Expected benefit payments for the year ending: | Pension Benefits | Other Postretirement Benefits before Medicare Part D Subsidy | Impact of Medicare Part D Subsidy |
|--|------------------|--|-----------------------------------|
| June 30, 2021 | \$ 127,688 | \$ 28,197 | \$ 152 |
| June 30, 2022 | 133,421 | 30,055 | 156 |
| June 30, 2023 | 141,527 | 32,073 | 159 |
| June 30, 2024 | 150,171 | 34,162 | 162 |
| June 30, 2025 | 158,907 | 36,129 | 165 |
| June 30, 2026 to June 30, 2030 | 915,914 | 209,711 | 852 |

Plan Assets and Allocations

The principal investment objectives for the pension and other postretirement benefits plans are to ensure the availability of funds to pay pension benefits as they become due under a broad range of future economic scenarios, to maximize long-term investment returns with an acceptable level of risk based on the pension obligations, and to invest the pension trust in a diversified manner.

Consolidated Notes to Financial Statements

The University's Office of Investments is responsible for the day-to-day management of the majority of the investments of the pension and other postretirement benefits. The investments are made in accordance with policies set out by the Investment Board which has been appointed by the Trustees. The pension and other postretirement benefit investments are similar in nature to those investments discussed in Notes 1 and 6 – Investments, at Fair Value. However, the actual allocations to specific investments within each asset class may vary due to certain restrictions imposed by investment managers and ERISA regulations.

A summary of plan assets, measured at fair value, as of June 30, 2020 and 2019, is as follows (in thousands):

Pension Benefits:

| Assets | Level 1 | Level 2 | Level 3 | Investments at NAV | 2020 |
|--------------------------|------------|------------|---------|--------------------|--------------|
| Short-term | \$ 49,251 | | | | \$ 49,251 |
| Equity: | | | | | |
| US equities | 197,651 | \$ 949 | | \$ 195,134 | 393,734 |
| International equities | 143,448 | | | 225,478 | 368,926 |
| Emerging market equities | 135 | | | 158,366 | 158,501 |
| Debt: | | | | | |
| US treasuries | 250,287 | 10,160 | | 1,944 | 262,391 |
| Corporate bonds | 121,245 | 114,848 | | 211,629 | 447,722 |
| Absolute return | | | | 660,490 | 660,490 |
| Real estate | | | | 76,464 | 76,464 |
| Private equity | 2,016 | | | 261,780 | 263,796 |
| Natural resources | 51,196 | | | 60,232 | 111,428 |
| Total assets | \$ 815,229 | \$ 125,957 | \$ - | \$ 1,851,517 | \$ 2,792,703 |

| Liabilities | Level 1 | Level 2 | Level 3 | Investments at NAV | 2020 |
|------------------------|---------|---------|---------|--------------------|--------|
| Derivative instruments | | \$ 368 | | | \$ 368 |
| Total liabilities | \$ - | \$ 368 | \$ - | \$ - | \$ 368 |

| Assets | Level 1 | Level 2 | Level 3 | Investments at NAV | 2019 |
|--------------------------|------------|-----------|---------|--------------------|--------------|
| Short-term | \$ 68,135 | | | | \$ 68,135 |
| Equity: | | | | | |
| US equities | 224,330 | \$ 459 | | \$ 165,882 | 390,671 |
| International equities | 126,403 | | | 234,903 | 361,306 |
| Emerging market equities | 191 | | | 163,689 | 163,880 |
| Debt: | | | | | |
| US treasuries | 358,601 | 7,699 | | 1,301 | 367,601 |
| Corporate bonds | 85,863 | 79,915 | | 188,261 | 354,039 |
| Absolute return | | | | 547,478 | 547,478 |
| Real estate | | | | 60,890 | 60,890 |
| Private equity | 2,611 | | | 221,968 | 224,579 |
| Natural resources | 68,499 | | | 89,928 | 158,427 |
| Total assets | \$ 934,633 | \$ 88,073 | \$ - | \$ 1,674,300 | \$ 2,697,006 |

| Liabilities | Level 1 | Level 2 | Level 3 | Investments at NAV | 2019 |
|------------------------|---------|---------|---------|--------------------|--------|
| Derivative instruments | | \$ 266 | | | \$ 266 |
| Total liabilities | \$ - | \$ 266 | \$ - | \$ - | \$ 266 |

Consolidated Notes to Financial Statements

Other Postretirement Benefits:

| Assets | Level 1 | Level 2 | Level 3 | Investments at NAV | 2020 |
|--------------------------|----------------|----------------|----------------|---------------------------|-------------|
| Short-term | \$ 28,467 | | | | \$ 28,467 |
| Equity: | | | | | |
| US equities | 4,685 | | | \$ 67,369 | 72,054 |
| International equities | | | | 82,376 | 82,376 |
| Emerging market equities | 70 | | | 43,251 | 43,321 |
| Debt: | | | | | |
| US treasuries | 20,692 | | | | 20,692 |
| Corporate bonds | | | | 11,077 | 11,077 |
| Absolute return | | | | 185,917 | 185,917 |
| Real estate | | | | 33,203 | 33,203 |
| Private equity | | | | 59,059 | 59,059 |
| Natural resources | 12,122 | | | 6,781 | 18,903 |
| Total | \$ 66,036 | \$ - | \$ - | \$ 489,033 | \$ 555,069 |

| Liabilities | Level 1 | Level 2 | Level 3 | Investments at NAV | 2020 |
|------------------------|----------------|----------------|----------------|---------------------------|-------------|
| Derivative instruments | | \$ 118 | | | \$ 118 |
| Total | \$ - | \$ 118 | \$ - | \$ - | \$ 118 |

| Assets | Level 1 | Level 2 | Level 3 | Investments at NAV | 2019 |
|--------------------------|----------------|----------------|----------------|---------------------------|-------------|
| Short-term | \$ 25,184 | | | | \$ 25,184 |
| Equity: | | | | | |
| US equities | | | | \$ 62,356 | 62,356 |
| International equities | | | | 79,723 | 79,723 |
| Emerging market equities | 4,409 | | | 48,233 | 52,642 |
| Debt: | | | | | |
| US treasuries | 22,771 | | | | 22,771 |
| Corporate bonds | | | | 10,702 | 10,702 |
| Absolute return | | | | 165,196 | 165,196 |
| Real estate | | | | 24,102 | 24,102 |
| Private equity | | | | 47,373 | 47,373 |
| Natural resources | 22,752 | | | 9,629 | 32,381 |
| Total | \$ 75,116 | \$ - | \$ - | \$ 447,314 | \$ 522,430 |

| Liabilities | Level 1 | Level 2 | Level 3 | Investments at NAV | 2019 |
|------------------------|----------------|----------------|----------------|---------------------------|-------------|
| Derivative instruments | | \$ 65 | | | \$ 65 |
| Total | \$ - | \$ 65 | \$ - | \$ - | \$ 65 |

As of June 30, 2020, the University has unfunded commitments to limited partnerships totaling \$270,012,000, which are expected to be called over the next 5 years.

Transfers between leveled assets are based on the actual date of the event which caused the transfer. As of June 30, 2020 and 2019 there were no transfers between Level 1 and 2.

Consolidated Notes to Financial Statements

Plan asset allocations by category are as follows:

| 2020 Allocation of Plan Assets | Pension Benefits | | Other Postretirement Benefits | |
|-----------------------------------|---------------------|--------|----------------------------------|--------|
| | Target | Actual | Target | Actual |
| Short-term | 0.0% | 1.8% | 0.0% | 5.1% |
| Equity: | | | | |
| US equities | 12.2% | 14.1% | 10.0% | 13.0% |
| International equities | 13.1% | 13.2% | 16.0% | 14.8% |
| Emerging markets equities | 6.0% | 5.7% | 10.0% | 7.8% |
| Debt: | | | | |
| US treasuries | 23.9% | 9.4% | 7.0% | 3.7% |
| Corporate bonds | 3.5% | 16.0% | 0.0% | 2.0% |
| Absolute return | 22.1% | 23.7% | 34.0% | 33.5% |
| Real estate | 2.7% | 2.7% | 4.0% | 6.0% |
| Private equity | 9.2% | 9.4% | 9.0% | 10.7% |
| Natural resources | 7.3% | 4.0% | 10.0% | 3.4% |
| Total | 100.0% | 100.0% | 100.0% | 100.0% |

12. Debt Obligations

Debt obligations at June 30, 2020 and 2019 are as follows (in thousands):

| | Final Maturity | Effective Interest Rate at June 30, 2020 | 2020 | 2019 |
|---|-------------------|--|--------------|--------------|
| Academic Component: | | | | |
| <u>Fixed rate debt obligations:</u> | | | | |
| The Trustees of the University of Pennsylvania | | | | |
| Series A of 2019 revenue bonds | 02/2119 | 3.61% | \$ 300,000 | |
| Series 2012 Taxable Bonds | 09/2112 | 4.67% | 300,000 | \$ 300,000 |
| Pennsylvania Higher Educational Facilities Authority (PHEFA) | | | | |
| Series B of 2019 revenue bonds | 02/2045 | 2.40% - 2.97% | 213,585 | |
| Series A of 2018 revenue bonds | 08/2048 | 2.08% - 4.70% | 183,145 | 183,145 |
| Series A of 2017 revenue bonds | 08/2046 | 2.26% - 3.72% | 178,395 | 178,395 |
| Series A of 2016 revenue bonds | 08/2041 | 1.08% - 2.93% | 120,680 | 167,435 |
| Series A of 2015 revenue bonds | 10/2045 | 1.40% - 2.63% | 49,125 | 191,090 |
| Series B of 2015 revenue bonds | 10/2038 | 1.40% - 3.38% | 159,460 | 160,950 |
| Series C of 2015 revenue bonds | 10/2035 | 3.68% | 8,020 | 8,020 |
| Series A of 2011 revenue bonds | 09/2021 | 3.49% - 3.68% | 7,590 | 7,590 |
| Series of 2010 revenue bonds | 09/2033 | | | 16,935 |
| Series B of 2009 revenue bonds | 09/2020 | 3.99% | 2,245 | 4,435 |
| Series C of 2009 revenue bonds | 09/2019 | | | 4,095 |
| Other loans | 05/2031 | 3.00% - 4.50% | 21,468 | 12,774 |
| <u>Variable rate debt obligations:</u> | | | | |
| PHEFA Series of 1990 revenue bonds | 12/2020 | 0.36% | 6,500 | 6,500 |
| Washington County Authority Series of 2004 | 07/2034 | 0.01% | 48,900 | 51,200 |
| Total Academic Component outstanding bonds payable | | | 1,599,113 | 1,292,564 |
| Unamortized issuance costs, premiums and discounts, net | | | 66,130 | 83,910 |
| Total Academic Component debt obligations | | | \$ 1,665,243 | \$ 1,376,474 |
| UPHS: | | | | |
| <u>Fixed rate debt obligations:</u> | | | | |
| Lancaster County Hospital Authority (LCHA) | | | | |
| Series A of 2016 revenue bonds | 08/2042 | 1.25% - 3.52% | \$ 156,455 | \$ 160,590 |
| Series B of 2016 revenue bonds | 08/2046 | 1.43% - 3.58% | 128,050 | 128,050 |
| PHEFA | | | | |
| Series A of 2019 revenue bonds | 08/2049 | 1.67% - 3.22% | 534,870 | |
| Series A of 2017 revenue bonds | 08/2047 | 2.60% - 3.68% | 400,000 | 400,000 |
| Series C of 2016 revenue bonds | 08/2041 | 0.94% - 3.08% | 128,435 | 128,730 |
| Series A of 2015 revenue bonds | 08/2045 | 1.60% - 4.00% | 257,495 | 278,975 |
| Series A of 2012 revenue bonds | 08/2042 | 2.27% - 4.08% | 134,650 | 136,360 |
| Series A of 2009 revenue bonds | 08/2021 | 4.52% - 4.67% | 12,115 | 22,780 |
| New Jersey Health Care Facilities Financing Authority (NJHCFFA) | | | | |
| Princeton Healthcare System Series A of 2016 | 07/2039 | 1.70% - 3.88% | 173,660 | 178,670 |
| University of Pennsylvania Health System Taxable Note | 08/2047 | 4.01% | 200,000 | 200,000 |
| Lancaster General Hospital 2015 Taxable Note | 08/2022 | 2.66% | 67,798 | 70,335 |
| Build to suit lease, net of related interest | Various | Various | | 75,094 |
| Line of credit, outstanding balance | Various | Various | | 87,000 |
| Mortgages, notes and other | Various | Various | 160,914 | 76,312 |
| <u>Variable rate debt obligations:</u> | | | | |
| PHEFA Series A of 2014 revenue bonds | 08/2044 | 1.30% | 100,000 | 100,000 |
| PHEFA Series A of 2008 revenue bonds | 08/2038 | 0.12% | 69,995 | 69,995 |
| NJHCFFA Princeton Healthcare System Series B of 2016 | 07/2045 | 0.66% | 65,000 | 65,000 |
| NJHCFFA Princeton Healthcare System Series C of 2016 | 07/2045 | 0.67% | 20,000 | 20,000 |
| Total UPHS outstanding bonds payable | | | 2,609,437 | 2,197,891 |
| Unamortized issuance costs, premiums and discounts, net | | | 181,480 | 132,128 |
| Total UPHS debt obligations | | | 2,790,917 | 2,330,019 |
| Total University debt obligations | | | \$ 4,456,160 | \$ 3,706,493 |

Consolidated Notes to Financial Statements

Contractual maturities of debt obligations are as follows (in thousands):

| Fiscal Year | Academic Component | UPHS | Total |
|--|-----------------------|--------------|--------------|
| 2021 | \$ 28,837 | \$ 98,663 | \$ 127,500 |
| 2022 | 25,455 | 54,266 | 79,721 |
| 2023 | 26,520 | 116,629 | 143,149 |
| 2024 | 35,151 | 58,712 | 93,863 |
| 2025 | 29,128 | 62,006 | 91,134 |
| Thereafter | 1,454,022 | 2,219,161 | 3,673,183 |
| Total Principal | 1,599,113 | 2,609,437 | 4,208,550 |
| Unamortized issuance costs, premiums & discounts | 66,130 | 181,480 | 247,610 |
| Total debt obligation | \$ 1,665,243 | \$ 2,790,917 | \$ 4,456,160 |

The University has letters of credit with various financial institutions to secure certain self-insured liabilities totaling \$19,096,000 and \$15,540,000 at June 30, 2020 and 2019, respectively, of which \$8,843,000 and \$7,829,000 were issued under a line of credit. The letters of credit have evergreen provisions for automatic renewal. There have been no draws under the letters of credit.

Academic Component

On August 6, 2019, the Trustees of the University of Pennsylvania (the "University") issued Taxable Bonds, Series A of 2019 in the aggregate principal amount of \$300,000,000. The proceeds of the sale of the Series A of 2019 Bonds will be used by the University for its general corporate purposes, including the financing or refinancing of capital projects and the payment of the cost of issuing the Series A of 2019 Bonds. Interest on the Series A of 2019 is fixed with coupons of 3.61%.

On August 14, 2019, Pennsylvania Higher Educational Facilities Authority (PHEFA) issued Series B of 2019 Taxable Refunding Revenue Bonds (PHEFA 2019B bonds) with an aggregate principal amount of \$213,585,000. The proceeds were used to fund an escrow which will be used to refund \$16,935,000 from the PHEFA Series 2010 revenue bonds, \$136,745,000 PHEFA Series A of 2015, and \$45,570,000 from the PHEFA Series A of 2016. The refunded bonds were legally defeased, and as such are no longer included among the University's reported liabilities. Interest on the PHEFA 2019B bonds is fixed with coupons ranging between 2.40% to 2.97%.

As a result of the legal defeasance of debt associated with the issuance of PHEFA 2019B bonds, the University reported a loss on early extinguishment of debt in Pension, OPEB and other net on the Consolidated Statements of Activities in the amount of \$3,618,000 for the year ended June 30, 2020.

On October 18, 2018, PHEFA issued Series A of 2018 revenue bonds (PHEFA 2018A bonds) with an aggregate principal amount of \$183,145,000. The proceeds were used to fund or reimburse the University for the cost of various capital projects. Interest on the PHEFA 2018A bonds is fixed with coupons ranging between 3.25% to 5.00%.

The University has variable rate debt in the amount of \$55,400,000 which is subject to optional tender by the holders upon seven days' notice. These bonds are reflected in the table above based on original scheduled maturities. In the event that the University receives notice of any optional tender on its variable rate demand bonds, the purchase price will be repaid from the remarketing of the bonds. However, in the event that the entire remarketing effort were to fail, the University would have the general obligation to purchase the bonds.

On June 14, 2016, the University entered into a five-year agreement with a financial institution, whereby the institution has agreed to provide a line of credit in the amount of \$100,000,000 for general purposes of the University. The University pays a fee annually on the unused amount of the line of credit. As of June 30, 2020, \$1,000,000 has been drawn under the agreement.

UPHS

The PHEFA Revenue Bonds, Lancaster County Hospital Authority (LCHA) Revenue Bonds and New Jersey Health Care Facilities Financing Authority (NJHCFFA) Revenue Bonds are secured by master notes issued under the UPHS Master Trust Indenture (MTI). The MTI and related agreements contain certain restrictive covenants which limit the issuance of additional indebtedness, and among other things, require UPHS to meet an annual debt service coverage requirement of “income available for debt service” (excess of revenue over expenses plus depreciation, amortization, interest expense and extraordinary items) at an amount equal to 110% of the annual debt service requirements. If the coverage requirement for a particular year is not met, within six months of the close of that fiscal year, UPHS must retain the services of a consultant to make recommendations to improve the coverage requirement. UPHS must also implement the recommendations of the consultant to the extent that they can be feasibly implemented. UPHS will not be considered to be in default of the provisions of the MTI so long as UPHS has sufficient cash flow to pay total operating expenses and debt service for the fiscal year. In both 2020 and 2019, UPHS met its debt service coverage requirement under the MTI. Additionally, UPHS has pledged its gross revenues to secure its obligation under the MTI.

On December 5, 2019, Pennsylvania Higher Educational Facilities Authority (PHEFA) issued UPHS Series A of 2019 revenue bonds in an aggregate principal amount of \$534,870,000. The proceeds were used to reimburse UPHS for \$484,738,000 million incurred in relation to various capital projects, and \$112,276,000 million of the remaining proceeds, including the issued premium, were deposited in a capital project fund held by trustee to be drawn upon for future capital expenditures. This portion of the financing is reflected as a noncash transaction in the Statement of Cash Flows. Future reimbursements from the capital project fund will be accounted for as a cash inflow from investing activities in the Statement of Cash Flows. The bonds have stated interest rates that range between 3.00% and 5.00%.

UPHS has variable rate debt in the amount of \$69,995,000 which is subject to optional tender by the holders upon seven days’ notice. These bonds are reflected in the debt obligations maturity table above based on original scheduled maturities. In the event that UPHS receives notice of any optional tender on its variable rate demand bonds, the purchase price will be repaid from the remarketing of the bonds. However, in the event that the entire remarketing effort were to fail, UPHS has in place a renewable direct pay letter of credit issued by Bank of America with an expiration date of April 15, 2023. In the event that the letter of credit cannot be drawn upon, UPHS would have the general obligation to purchase the bonds.

UPHS secured an \$82,132,000 loan on December 21, 2018 for the sole purpose of funding the development of a new ambulatory building. As of June 30, 2020, the entire balance has been drawn down to reimburse construction costs incurred by UPHS and is accounted for as a cash inflow from investing activities in the Statement of Cash Flows.

Upon adoption of the new accounting standard for leases, UPHS derecognized a build-to-suit lease liability of \$75,094,000 from Debt obligations with a corresponding asset of \$67,307,000 from PPE, resulting in a gain of \$8,022,000 recorded in Pension, OPEB and other, net. The remainder of the lease was accounted for as an operating lease under the new leasing guidance.

UPHS maintains lines of credit in the amount of \$250,000,000 to supplement liquidity and issue letters of credit to cover balances due on construction projects and reinsurance agreements. On April 7, 2020, UPHS entered into a one-year agreement with a commercial bank for \$150,000,000 line of credit which was immediately drawn down to provide additional liquidity during the COVID-19 pandemic. The remaining \$100,000,000 has a maturity of April 13, 2022. The outstanding balance as of June 30, 2020 and 2019 was \$0 and \$87,000,000, respectively.

Consolidated Notes to Financial Statements

Interest Rate Swap Agreements

The University enters into interest rate swap agreements to synthetically modify the interest rate terms of its long term debt portfolio. These agreements are not entered into for trading or speculative purposes. Fair value of these agreements is determined by obtaining quotes from Goldman Sachs Mitsui Marine Derivative Products, L.P. (GSMMDP) and Merrill Lynch, respectively, which are based on the income approach, using observable market data to discount future net payment streams and accordingly considers this to be a Level 2 measurement. The quotes provided also represent the amount the University would accept or be required to pay to transfer the agreement to GSMMDP and Merrill Lynch, respectively, or exit price as defined by the Fair Value Measurements standard. The University also takes into account the risk of nonperformance.

The following table summarizes the terms of the University's remaining interest rate swap agreements (in thousands):

| | Academic Component | UPHS | | | |
|------------------|----------------------|----------------------|-------------|-------------|--|
| Notional Amounts | \$ 101,950 | \$ 21,550 | \$ 14,355 | \$ 14,355 | |
| Trade Date | 11/6/2007 | 7/28/2006 | 7/15/2009 | 1/7/2010 | |
| Maturity Date | 7/1/2034 | 7/1/2041 | 8/15/2023 | 8/15/2023 | |
| Rates: | | | | | |
| Receive | 67% of 1-Month LIBOR | 70% of 1-month LIBOR | 3.184% | 2.902% | |
| Pay | 3.573% | 3.980% | SIFMA index | SIFMA index | |

The following tables summarize the fair value of the interest rate swap agreements, not designated as hedging instruments, as of June 30, 2020 and 2019, and the related gains/(losses) on the interest rate swap agreements, both realized and unrealized, for the years ended June 30, 2020 and 2019 (in thousands):

| Consolidated Statements of Financial Position | Line Item | 2020 | 2019 |
|---|--|------------|------------|
| <u>Asset interest rate swaps</u> | | | |
| UPHS | Other assets | \$ 1,425 | \$ 1,469 |
| Total Asset interest rate swaps | | \$ 1,425 | \$ 1,469 |
| <u>Liability interest rate swaps</u> | | | |
| Academic Component | Accrued expenses and other liabilities | \$ 28,801 | \$ 21,379 |
| UPHS | Accrued expenses and other liabilities | 8,854 | 6,371 |
| Total Liability interest rate swaps | | \$ 37,655 | \$ 27,750 |
| Consolidated Statements of Activities | Line Item | 2020 | 2019 |
| Academic Component | Return on investments, net | \$ (9,772) | \$ (7,497) |
| UPHS | Return on investments, net | 511 | 737 |
| Total | | \$ (9,261) | \$ (6,760) |

13. Net Assets

The major components of net assets at June 30, 2020 and 2019 are as follows (in thousands):

| 2020 | | Without donor restrictions | | With donor restrictions | | Total |
|-------------------------------------|----|---------------------------------------|----|------------------------------------|----|--------------|
| General operating | \$ | 3,931,320 | \$ | 503,062 | \$ | 4,434,382 |
| Sponsored programs | | 63,592 | | | | 63,592 |
| Capital | | | | 130,462 | | 130,462 |
| Student loans | | 7,713 | | | | 7,713 |
| Planned giving agreements | | | | 52,757 | | 52,757 |
| Quasi-endowment | | 7,363,736 | | | | 7,363,736 |
| Endowment, subject to spending rule | | | | 3,109,738 | | 3,109,738 |
| Endowment, held in perpetuity | | | | 4,403,889 | | 4,403,889 |
| Total | \$ | 11,366,361 | \$ | 8,199,908 | \$ | 19,566,269 |

| 2019 | | Without donor restrictions | | With donor restrictions | | Total |
|-------------------------------------|----|---------------------------------------|----|------------------------------------|----|--------------|
| General operating | \$ | 4,085,420 | \$ | 449,779 | \$ | 4,535,199 |
| Sponsored programs | | 44,217 | | | | 44,217 |
| Capital | | | | 133,693 | | 133,693 |
| Student loans | | 10,387 | | | | 10,387 |
| Planned giving agreements | | | | 51,576 | | 51,576 |
| Quasi-endowment | | 7,252,228 | | | | 7,252,228 |
| Endowment, subject to spending rule | | | | 3,203,289 | | 3,203,289 |
| Endowment, held in perpetuity | | | | 4,194,244 | | 4,194,244 |
| Total | \$ | 11,392,252 | \$ | 8,032,581 | \$ | 19,424,833 |

14. Leases

The University leases research labs and office space under operating leases expiring through December 2043. Under the newly adopted accounting standard for leases, a lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. On the Consolidated Statements of Financial Position, lessees are required to record Right-of-Use assets, representing the right to use the underlying assets for the lease term, and Lease liabilities, representing the obligation to make lease payments arising from the lease based on the present value of lease payments over the lease term. The University has made the following elections: (1) to adopt a package of practical expedients relating to reassessment, (2) to exclude leases with a term of less than one year, and (3) to use an incremental borrowing rate for discounting leases, as applicable. At June 30, 2020, Right-of-Use assets recorded in Other assets were \$438,368,000 and Lease liabilities recorded in Accrued expenses and other liabilities were \$447,778,000. At June 30, 2020, the weighted average remaining lease term was 10.6 years and the weighted average discount rate was 3.55%. Rental expense, totaling \$136,529,000 (including amortizations related to Right-of-Use assets and Lease liabilities of \$68,189,000) and \$120,960,000, for the years ended June 30, 2020 and 2019, respectively, is included in Other operating expenses on the Consolidated Statements of Activities.

Consolidated Notes to Financial Statements

Future maturities of lease liabilities at June 30, 2020 are as follows (in thousands):

| | |
|-----------------------------|------------|
| Year ending June 30, | |
| 2021 | \$ 70,862 |
| 2022 | 64,262 |
| 2023 | 54,887 |
| 2024 | 50,878 |
| 2025 | 45,651 |
| Thereafter | 267,196 |
| Total lease payments | \$ 553,736 |
| Less imputed interest | (105,958) |
| Total Future lease payments | \$ 447,778 |

Future minimum lease payments at June 30, 2019 (prior to newly adopted standard) were as follows (in thousands):

| | |
|------------------------------|------------|
| Year ending June 30, | |
| 2020 | \$ 101,735 |
| 2021 | 88,750 |
| 2022 | 78,748 |
| 2023 | 67,668 |
| 2024 | 63,082 |
| Thereafter | 310,212 |
| Total minimum lease payments | \$ 710,195 |

15. Functional Classification of Expenditures

Expenses for the years ended June 30, 2020 and 2019 are categorized on a functional basis as follows (in thousands):

| | 2020 | | | | | |
|---------------------------------------|--|-----------------------------------|------------|--------------------------|--|---------------|
| | Instruction, student services & academic support | Hospital & physician practices | Research | Institutional support | Enterprises & independent operations | Total |
| Compensation and benefits | \$ 1,095,779 | \$ 4,256,950 | \$ 490,783 | \$ 266,324 | \$ 203,832 | \$ 6,313,668 |
| Depreciation and amortization | 88,149 | 324,642 | 44,648 | 20,510 | 57,054 | 535,003 |
| Interest on indebtedness | 16,027 | 36,741 | 23,637 | 207 | 11,148 | 87,760 |
| Other operating expense | 532,648 | 2,929,459 | 332,312 | 42,231 | 171,605 | 4,008,255 |
| Total operating expense | 1,732,603 | 7,547,792 | 891,380 | 329,272 | 443,639 | 10,944,686 |
| Non-service net periodic benefit cost | 1,880 | 7,302 | 842 | 457 | 350 | 10,831 |
| Total | \$ 1,734,483 | \$ 7,555,094 | \$ 892,222 | \$ 329,729 | \$ 443,989 | \$ 10,955,517 |

| | 2019 | | | | | |
|---------------------------------------|--|-----------------------------------|------------|--------------------------|--|---------------|
| | Instruction, student services & academic support | Hospital & physician practices | Research | Institutional support | Enterprises & independent operations | Total |
| Compensation and benefits | \$ 1,044,075 | \$ 4,026,781 | \$ 466,938 | \$ 257,576 | \$ 195,821 | \$ 5,991,191 |
| Depreciation and amortization | 86,651 | 332,813 | 43,898 | 20,147 | 56,726 | 540,235 |
| Interest on indebtedness | 7,789 | 54,492 | 23,665 | 296 | 8,568 | 94,810 |
| Other operating expense | 564,089 | 2,727,834 | 347,405 | 44,087 | 189,287 | 3,872,702 |
| Total operating expense | 1,702,604 | 7,141,920 | 881,906 | 322,106 | 450,402 | 10,498,938 |
| Non-service net periodic benefit cost | 619 | 2,386 | 277 | 153 | 115 | 3,550 |
| Total | \$ 1,703,223 | \$ 7,144,306 | \$ 882,183 | \$ 322,259 | \$ 450,517 | \$ 10,502,488 |

Operation and maintenance of PPE and depreciation are allocated to functional classifications based on square footage. Interest expense is generally allocated to functional classifications of the activity that directly benefited from the proceeds of the debt. Non-service net periodic benefit cost is allocated to functional classifications based on compensation and benefits.

16. Liquidity and Availability

As of June 30, 2020 and 2019, respectively, financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, scheduled principal payments on debt and capital construction costs not financed with debt, were as follows (in thousands):

| | 2020 | 2019 |
|--|---------------|---------------|
| Financial assets: | | |
| Cash & cash equivalents | \$ 2,117,979 | \$ 1,375,469 |
| Receivables, net | 1,213,513 | 1,217,065 |
| Pledge payments available for operations | 65,559 | 75,598 |
| Investments | 7,103,005 | 7,958,710 |
| Total financial assets available within one year | 10,500,056 | 10,626,842 |
| Liquidity resources: | | |
| Bank lines of credit | 340,157 | 113,000 |
| Total financial assets and liquidity resources available within one year | \$ 10,840,213 | \$ 10,739,842 |

The University's cash flows have seasonal variations during the year attributable to tuition billing, patient service reimbursement and a concentration of contributions received at calendar and fiscal year-end. To manage liquidity, the University maintains lines of credit with several banks that are drawn upon as needed during the year to manage cash flows. Management has the discretion to utilize the full amount of quasi-endowment funds for general expenditures.

17. Subsequent Events

The University has evaluated subsequent events for the period from June 30, 2020 through October 7, 2020, the date the consolidated financial statements were issued.

On July 14, 2020, the University issued Taxable Bonds, Series A of 2020 in the aggregate principal amount of \$300,000,000. The proceeds of the sale of the Series A of 2020 Bonds will be used by the University for its general corporate purposes, including the financing or refinancing of capital projects and the payment of the cost of issuing the Series A of 2020 Bonds. Interest on the Series A of 2020 is fixed with coupons of 2.396%.

Trustees of the University of Pennsylvania

As of June 30, 2020

David L. Cohen, Esq., L'81, Chair
Mr. Robert M. Levy, WG'74, Vice Chair

Trustees

Ms. Laura J. Alber, C'90
Mrs. Bonnie Miao Bandeen, C'80, WG'85
Mr. Michawel L. Barrett, ENG'89
Mr. Brett H. Barth, W'93
Mr. Adam K. Bernstein, W'85
Mr. David S. Blitzler, W'91w
Scott L. Bok, Esq., C'81, W'81, L'84
Mr. William Polk Carey II, WG'19
Mr. James G. Dinan, W'81
Mrs. Lee Spelman Doty, W'76
Mrs. Connie K. Duckworth, WG'79
Mr. Alberto I. Duran, WG'93
Mr. David Ertel, W'87, WG'88
Mr. Christopher H. Franklin
Mr. Michael F. Gerber, C'95
Perry Golkin, Esq., W'74, WG'74, L'78
Mr. James H. Greene, Jr., W'72
Dr. Amy Gutmann, Ex Officio
Mr. Andrew R. Heyer, W'79, WG'79
Mr. George Kwok Lung Hongchoy, WG'91
Mr. Lloyd W. Howell, Jr., ENG'88
Osagie O. Imasogie, Esq., GL'85
Mrs. Lynn J. Jerath, W'95
James C. Johnson, Esq., C'74, L'77
Susanna E. Lachs, Esq., CW'74, ASC'76
Mr. William P. Lauder, W'83
Mr. Charles B. Leitner III, C'81
M. Claire Lomax, Esq., C'84
Ms. Catherine M. O'Hern Lyons, C'86
Dr. Patricia Martin, M'85
Mr. Marc F. McMorris, C'90, WG'94
Mr. Kenneth D. Moelis, W'80, WG'81
Mr. Ofer Nemirovsky, EE'79, W'79
Mr. Dhananjay M. Pai, W'83
Mrs. Cheryl Peisach, W'87
Mr. Kevin S. Penn, W'83
Mr. Richard C. Perry, W'77
Mrs. Julie Beren Platt, C'79
Mr. Michael J. Price, W'79
Mr. Andrew S. Rachleff, W'80
Mr. Ramanan Raghavendran, ENG'89, W'89, LPS'15
Mrs. Ann Reese, CW'74
Mr. Marc J. Rowan, W'84, WG'85
Mr. Theodore E. Schlein, C'86
Mr. Alan D. Schnitzer, W'88

Mrs. Julie Breier Seaman, C'86
Mr. John P. Shoemaker, C'87
Amb. Martin J. Silverstein, GL'o8
Ms. Stacey G. Snider, C'82
Mr. Robert M. Stavis, EAS'84, W'84
Mr. Richard Vague
Mrs. Jill Topkis Weiss, C'89, WG'93
Mr. Mark B. Werner, C'80
Hon. Tom Wolf, Ex Officio

Emeritus

Mrs. Judith L. Bollinger, WG'81
Gilbert F. Casellas, Esq., L'77
Mrs. Susan W. Catherwood
William W.M. Cheung, DMD, D'81, GD'82
Dr. Gloria Twine Chisum, Gr'60, Hon'94
Mr. L. John Clark, W'63, WG'68
Mr. Robert A. Fox, C'52
Mr. Stephen J. Heyman, W'59
Mr. Paul K. Kelly, C'62, WG'64
Mr. James J. Kim, W'59, G'61, Gr'63
Mr. Michael J. Kowalski, W'74
Mrs. Andrea Berry Laporte, Nu'69
Mr. Leonard A. Lauder, W'54
Mr. William L. Mack, W'61
Mr. A. Bruce Mainwaring, C'47
Mr. Howard S. Marks, W'67
Mr. Edward J. Mathias, C'64
Ms. Andrea Mitchell, CW'67
Mr. Russell E. Palmer, Hon'84
Mr. Ronald O. Perelman, W'64, WG'66
Mr. Egbert L. J. Perry, CE'76, WG'78, GCE'79
Mr. James S. Riepe, W'65, WG'67, Hon'10
Mrs. Katherine Stein Sachs, CW'69
Mrs. Adele K. Schaeffer, CW'55
Mr. Alvin V. Shoemaker, W'60, Hon'95
Dr. Krishna P. Singh, GME'69, Gr'72
Dr. P. Roy Vagelos, C'50, Hon'99
Mr. George A. Weiss, W'65, Hon'14
Dr. Charles K. Williams II, Gr'78, Hon'97
Mr. Paul Williams, W'67
Mr. Mark O. Winkelman, WG'73

Honorary

John G. Harkins, Jr., Esq., C'53, L'58
Mrs. Margaret R. Mainwaring, Ed'47, Hon'85

Statutory Officers

As of August 1, 2020

President

Dr. Amy Gutmann

Provost

Dr. Wendell E. Pritchett

Executive Vice President

Mr. Craig R. Carnaroli

Executive Vice President of the University of Pennsylvania for the Health System and Dean, Perelman School of Medicine

Dr. J. Larry Jameson

Senior Vice President and Chief of Staff

Mr. Gregory Rost

Senior Vice President and General Counsel of the University of Pennsylvania and the University of Pennsylvania Health System

Wendy S. White, Esq.

Senior Vice President for Development and Alumni Relations

Mr. John H. Zeller

Senior Vice President for Institutional Affairs and Chief Diversity Officer

Ms. Joann Mitchell

Vice President for Audit, Compliance, and Privacy

Mr. Gregory J. Pellicano

Vice President, Budget Planning and Analysis

Mr. Trevor C. Lewis

Vice President for Business Services

Ms. Marie Witt

Vice President for Facilities and Real Estate Services

Ms. Anne Papageorge

Vice President for Finance and Treasurer

Ms. MaryFrances McCourt

Vice President for Government and Community Affairs

Mr. Jeffrey Cooper

Vice President for Human Resources

Dr. John J. Heuer

Vice President for Information Technology and University Chief Information Officer

Mr. Thomas H. Murphy

Vice President for Institutional Research & Analysis

Dr. Stacey J. Lopez

Vice President for Public Safety

Ms. Maureen Rush

Vice President for Social Equity and Community

Dr. Charles L. Howard

Vice President for University Communications

Mr. Stephen J. MacCarthy

Vice President and University Secretary

Ms. Medha Narvekar

Comptroller

Mr. Russell Di Leo

**“Doors to wisdom are
never shut.”**

